

Olaparib for Metastatic Breast Cancer in Patients with a

New England Journal of Medicine

377, 523-533

DOI: [10.1056/nejmoa1706450](https://doi.org/10.1056/nejmoa1706450)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Malignant external otitis. <i>Journal of Laryngology and Otology</i> , 1987, 101, 205-210.	0.4	62
2	Atrial fibrillation. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16017.	18.1	6
3	Olaparib improves PFS. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 460-460.	12.5	0
4	Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. <i>Clinical Oncology</i> , 2017, 29, 778-786.	0.6	13
5	Olaparib for Metastatic Germline <i>BRCA</i> -Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 1792-1793.	13.9	55
6	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1637-1651.	5.1	233
7	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). <i>Breast</i> , 2017, 35, 203-217.	0.9	203
8	Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. <i>Drug Resistance Updates</i> , 2017, 32, 1-15.	6.5	132
9	Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 911-917.	1.1	14
10	Genetic testing in women with breast cancer: implications for treatment. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 991-1002.	1.1	9
11	Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions. <i>Cancer Discovery</i> , 2017, 7, 937-939.	7.7	33
12	Fertility and pregnancy issues in <i>BRCA</i> -mutated breast cancer patients. <i>Cancer Treatment Reviews</i> , 2017, 59, 61-70.	3.4	68
13	PARP Inhibitors in Breast Cancer: Latest Evidence. <i>Current Breast Cancer Reports</i> , 2017, 9, 188-194.	0.5	0
15	Targeting PI3K/AKT pathway in triple-negative breast cancer. <i>Lancet Oncology</i> , The, 2017, 18, 1293-1294.	5.1	39
17	Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7521-7530.	3.2	144
18	Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer. <i>Trends in Molecular Medicine</i> , 2017, 23, 1121-1137.	3.5	48
19	De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 457-465.	1.7	60
20	Signatures of DNA-Repair Deficiencies in Breast Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 2490-2492.	13.9	21

#	ARTICLE	IF	CITATIONS
21	Update Breast Cancer 2017 – Implementation of Novel Therapies. Geburtshilfe Und Frauenheilkunde, 2017, 77, 1281-1290.	0.8	19
22	New agents for the management of resistant metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1815-1831.	0.9	5
23	Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers, 2017, 9, 109.	1.7	36
24	Emerging treatment options for ovarian cancer: focus on rucaparib. International Journal of Women's Health, 2017, Volume 9, 913-924.	1.1	19
25	ASCO 2017 – making a difference in cancer care with you. Memo - Magazine of European Medical Oncology, 2017, 10, 187-189.	0.3	0
26	Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype. Oncotarget, 2017, 8, 73329-73344.	0.8	64
27	Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines. Oncotarget, 2017, 8, 95316-95331.	0.8	35
28	Complexities of Variant Classification in Clinical Hereditary Cancer Genetic Testing. Journal of Clinical Oncology, 2017, 35, 3796-3799.	0.8	10
29	The OlympiAD trial: who won the gold?. Ecancermedicalsecience, 2017, 11, ed75.	0.6	7
30	Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Research and Treatment, 2018, 170, 101-109.	1.1	18
31	Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 18.	0.4	6
32	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 497-509.	5.1	530
34	Recent advances in precision oncology research. Npj Precision Oncology, 2018, 2, 11.	2.3	39
35	PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer, 2018, 124, 2498-2506.	2.0	101
36	Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. Current Treatment Options in Oncology, 2018, 19, 22.	1.3	60
37	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Annals of Oncology, 2018, 29, 1203-1210.	0.6	280
39	An ¹⁸ F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent. Journal of Medicinal Chemistry, 2018, 61, 4103-4114.	2.9	19
40	Development of capability for genome-scale CRISPR-Cas9 knockout screens in New Zealand. Journal of the Royal Society of New Zealand, 2018, 48, 245-261.	1.0	1

#	ARTICLE	IF	CITATIONS
41	Update on PARP Inhibitors in Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 21.	1.3	92
42	A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1392-1404.	1.9	23
43	PARP inhibitors and breast cancer: highlights and hang-ups. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 83-94.	0.4	4
44	News from the San Antonio Breast Cancer Symposium 2017. <i>Breast Care</i> , 2018, 13, 59-63.	0.8	0
45	Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells. <i>DNA Repair</i> , 2018, 63, 1-9.	1.3	35
46	Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents. <i>Drugs and Aging</i> , 2018, 35, 93-115.	1.3	6
47	Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients. <i>Journal of the American College of Surgeons</i> , 2018, 226, 560-565.	0.2	19
48	Individualizing the Approach to the Older Woman with Triple-Negative Breast Cancer. , 2018, , 159-177.		0
49	Impact of an embedded genetic counselor on breast cancer treatment. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 43-46.	1.1	35
51	Breast cancer: The translation of big genomic data to cancer precision medicine. <i>Cancer Science</i> , 2018, 109, 497-506.	1.7	92
52	Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management. , 2018, , 579-594.		1
53	Predictors of survival for breast cancer patients with a BRCA1 mutation. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 513-521.	1.1	20
54	BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. <i>Clinical Breast Cancer</i> , 2018, 18, 184-188.	1.1	34
55	The development of PARP as a successful target for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 161-175.	1.1	16
56	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. <i>Chemical Reviews</i> , 2018, 118, 1599-1663.	23.0	64
57	Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. <i>Seminars in Cancer Biology</i> , 2018, 51, 22-35.	4.3	115
58	Triple-Negative Breast Cancer. , 2018, , .		0
59	Management of Metastatic Triple-Negative Breast Cancer. , 2018, , 95-116.		0

#	ARTICLE	IF	CITATIONS
60	Molecular Profiling and Targeted Therapy for Triple-Negative Breast Cancer. , 2018, , 117-140.		0
61	The Genetics of Triple-Negative Breast Cancer. , 2018, , 33-40.		0
62	Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer. Clinical Breast Cancer, 2018, 18, e1229-e1235.	1.1	20
63	Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness. Annals of Oncology, 2018, 29, 18-21.	0.6	18
64	Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells. Oncology Reports, 2018, 39, 2261-2269.	1.2	3
65	The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. Cancer Treatment Reviews, 2018, 67, 34-44.	3.4	71
66	Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience. Breast, 2018, 40, 60-66.	0.9	5
67	Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature Medicine, 2018, 24, 628-637.	15.2	649
68	Checkpoint Inhibitors in the Treatment of Breast Cancer. Current Oncology Reports, 2018, 20, 51.	1.8	10
69	The emerging clinical relevance of genomics in cancer medicine. Nature Reviews Clinical Oncology, 2018, 15, 353-365.	12.5	351
70	Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist, 2018, 23, 697-703.	1.9	12
71	PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opinion on Emerging Drugs, 2018, 23, 123-133.	1.0	24
72	Clinical Usefulness of the Histoculture Drug Response Assay for Breast Cancer. Methods in Molecular Biology, 2018, 1760, 93-100.	0.4	2
73	Update Breast Cancer 2018 (Part 2) â€œ Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Und Frauenheilkunde, 2018, 78, 246-259.	0.8	23
74	Isoorientin triggers apoptosis of hepatoblastoma by inducing DNA double-strand breaks and suppressing homologous recombination repair. Biomedicine and Pharmacotherapy, 2018, 101, 719-728.	2.5	11
75	Targeting the replication stress response in cancer. , 2018, 188, 155-167.		124
76	Olaparib for the treatment of breast cancer. Expert Review of Anticancer Therapy, 2018, 18, 519-530.	1.1	37
77	Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screeningâ€”Reply. JAMA Oncology, 2018, 4, 883.	3.4	0

#	ARTICLE	IF	CITATIONS
78	Hereditary breast cancer: molecular biology and management update. <i>International Journal of Clinical Oncology</i> , 2018, 23, 35-35.	1.0	0
79	Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastogenesis. <i>Bone</i> , 2018, 106, 156-166.	1.4	29
80	Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. <i>Annals of Oncology</i> , 2018, 29, 154-161.	0.6	161
81	PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. <i>Clinical Pharmacokinetics</i> , 2018, 57, 427-437.	1.6	87
82	Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e135-e142.	1.1	17
83	Spurring science, marking progress, and influencing history. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 79-80.	12.5	3
84	Triple negative breast cancer in Asia: An insider's view. <i>Cancer Treatment Reviews</i> , 2018, 62, 29-38.	3.4	148
85	Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	215
86	Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	1.5	16
87	Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib. <i>Medicine (United States)</i> , 2018, 97, e13113.	0.4	17
88	Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. <i>JCO Precision Oncology</i> , 2018, 2, 1-9.	1.5	30
89	Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. <i>Journal of Clinical Oncology</i> , 2018, 36, 3134-3143.	0.8	43
90	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 1020-1044.	0.8	108
91	Targeting DNA Repair in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1017-1019.	0.8	4
92	Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	98
93	Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?. <i>Journal of Oncology Practice</i> , 2018, 14, 281-289.	2.5	11
94	Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations. <i>JCO Precision Oncology</i> , 2018, 2, 1-7.	1.5	15
95	Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1218-1224.	0.8	59

#	ARTICLE	IF	CITATIONS
96	Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 65-77.	1.8	11
97	Pathogenic Germline <i>BRCA1/2</i> Mutations and Familial Predisposition to Gastric Cancer. JCO Precision Oncology, 2018, 2, 1-8.	1.5	9
98	Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2018, 36, 523-524.	0.8	2
101	The Winds of Change: Emerging Therapeutics in Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 382-390.	1.8	2
102	Innovations and Challenges in the Treatment of Metastatic Triple-Negative Breast Cancer. Journal of Oncology Practice, 2018, 14, 290-291.	2.5	3
103	Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstetrics and Gynecology, 2018, 132, 1121-1129.	1.2	24
104	Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. Journal of Gastrointestinal Oncology, 2018, 9, 1198-1206.	0.6	6
107	Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer. JCO Precision Oncology, 2018, 2, 1-8.	1.5	2
108	Should We Lower Our Threshold for Germline Genetic Assessment in Pancreatic Adenocarcinoma?. JCO Precision Oncology, 2018, 2, 1-4.	1.5	2
109	Reclassification of <i>BRCA1</i> and <i>BRCA2</i> variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort. Journal of Medical Genetics, 2018, 55, 794-802.	1.5	25
110	Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591880850.	1.4	30
111	Inhibition of AKT suppresses the initiation and progression of <i>BRCA1</i> -associated mammary tumors. International Journal of Biological Sciences, 2018, 14, 1769-1781.	2.6	11
112	Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study. Targeted Oncology, 2018, 13, 725-733.	1.7	28
113	Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 459-464.	0.7	4
114	Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition. Cancers, 2018, 10, 453.	1.7	14
115	Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). BMC Cancer, 2018, 18, 1074.	1.1	12
116	Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19-23 October 2018. Targeted Oncology, 2018, 13, 673-677.	1.7	1
117	Precision oncology: separating the wheat from the chaff. ESMO Open, 2018, 3, e000446.	2.0	37

#	ARTICLE	IF	CITATIONS
118	The Inherited Cancer Registry (ICARE) Initiative: An Academic-Community Partnership for Patients and Providers. <i>Oncology Issues</i> , 2018, 33, 54-63.	0.0	7
119	Progress in Breast Cancer—Can We Do Better?. <i>Current Oncology</i> , 2018, 25, 7-8.	0.9	0
120	Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC). <i>Current Breast Cancer Reports</i> , 2018, 10, 282-288.	0.5	1
121	Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy. <i>Oncotarget</i> , 2018, 9, 32642-32652.	0.8	16
122	Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. <i>Cancers</i> , 2018, 10, 514.	1.7	141
124	Targeting Cancer Stem Cells to Overcome Chemoresistance. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4036.	1.8	106
125	Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. <i>Cancers</i> , 2018, 10, 506.	1.7	40
126	Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. <i>Cancers</i> , 2018, 10, 487.	1.7	154
127	Development of PARP and Immune-Checkpoint Inhibitor Combinations. <i>Cancer Research</i> , 2018, 78, 6717-6725.	0.4	155
128	Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2018, 16, 108-117.	0.2	0
129	Update Breast Cancer 2018 (Part 4) —“ Genomics, Individualized Medicine and Immune Therapies —“ in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1119-1128.	0.8	3
130	Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2507-2518.	1.9	20
131	Updates on Molecular Classification of Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2018, 10, 289-295.	0.5	1
132	PARP inhibition in platinum-based chemotherapy: Chemopotential and neuroprotection. <i>Pharmacological Research</i> , 2018, 137, 104-113.	3.1	38
133	Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Oncology Research and Treatment</i> , 2018, 41, 619-625.	0.8	11
134	Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1266.	3.8	186
135	Role of DNA Repair in Carcinogenesis and Cancer Therapeutics. , 2018, , 363-363.		0
136	Emerging PARP inhibitors for treating breast cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 211-221.	1.0	10

#	ARTICLE	IF	CITATIONS
137	Providerâ€™s Perceptions of Barriers and Facilitators for Latinas to Participate in Genetic Cancer Risk Assessment for Hereditary Breast and Ovarian Cancer. <i>Healthcare (Switzerland)</i> , 2018, 6, 116.	1.0	20
138	BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. <i>Cell Reports</i> , 2018, 24, 3513-3527.e7.	2.9	61
139	Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2018, 73, 123-135.	0.8	10
140	Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. <i>European Journal of Cancer</i> , 2018, 104, 160-168.	1.3	14
141	GÃ©nominique du cancer du sein appliquÃ©e aux traitements. <i>Revue Francophone Des Laboratoires</i> , 2018, 2018, 52-60.	0.0	0
142	Precision medicine based on tumorigenic signaling pathways for tripleâ€™negative breast cancer (Review). <i>Oncology Letters</i> , 2018, 16, 4984-4996.	0.8	27
143	A <sc>RAD</sc> 51 assay feasible in routine tumor samples calls <sc>PARP</sc> inhibitor response beyond <sc>BRCA</sc> mutation. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	169
144	Genomic analysis of DNA repair genes and androgen signaling in prostate cancer. <i>BMC Cancer</i> , 2018, 18, 960.	1.1	55
146	Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. <i>Advances in Therapy</i> , 2018, 35, 1945-1964.	1.3	12
147	Optimizing poly (<sc>ADP</sc>â€™ribose) polymerase inhibition through combined epigenetic and immunotherapy. <i>Cancer Science</i> , 2018, 109, 3383-3392.	1.7	28
148	Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. <i>BMC Medical Genetics</i> , 2018, 19, 185.	2.1	8
149	Major clinical research advances in gynecologic cancer in 2017. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e31.	1.0	19
150	Resurrection of PARP Inhibitors in Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1150-1156.	2.3	18
151	A contemporary review of male breast cancer: current evidence and unanswered questions. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 599-614.	2.7	63
152	Antibodyâ€™drug conjugates in triple negative breast cancer. <i>Future Oncology</i> , 2018, 14, 2651-2661.	1.1	23
153	SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 204-207.	0.3	3
154	Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma. <i>Clinical Sarcoma Research</i> , 2018, 8, .	2.3	3
155	ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2462-2472.	1.9	59

#	ARTICLE	IF	CITATIONS
156	Advances in the use of PARP inhibitor therapy for breast cancer. <i>Drugs in Context</i> , 2018, 7, 1-30.	1.0	101
157	The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer. <i>Laboratory Investigation</i> , 2018, 98, 1562-1574.	1.7	30
159	How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. <i>ESMO Open</i> , 2018, 3, e000357.	2.0	112
160	NCCN Guidelines Updates: Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 605-610.	2.3	135
161	Challenges with biomarkers in cancer drug discovery and development. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 685-690.	2.5	28
162	Biomarkers for Homologous Recombination Deficiency in Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 704-713.	3.0	223
163	Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance. <i>EBioMedicine</i> , 2018, 32, 111-118.	2.7	70
164	An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer. <i>Cell Death and Differentiation</i> , 2018, 25, 2209-2220.	5.0	94
165	Updates in the Evaluation and Management of Breast Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 794-807.	1.4	39
166	Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2018, 3, e000361.	2.0	49
167	Synthetic lethal therapies for cancer: what's next after PARP inhibitors?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 564-576.	12.5	303
168	Clinical and molecular aspects of breast cancer: Targets and therapies. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 14-34.	2.5	49
169	Poly(ADP-ribose) polymerase-1 promotes recruitment of meiotic recombination-1 to chromatin and DNA double-strand break repair in Ku70-deficient breast cancer cells. <i>FASEB Journal</i> , 2018, 32, 6112-6122.	0.2	6
170	When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age. <i>Annals of Internal Medicine</i> , 2018, 169, 233.	2.0	20
171	Interference with DNA repair after ionizing radiation by a pyrrole-imidazole polyamide. <i>PLoS ONE</i> , 2018, 13, e0196803.	1.1	4
172	Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , 2018, , .	1.8	5
173	Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. <i>Journal of the National Cancer Institute</i> , 2018, 110, 855-862.	3.0	225
174	Genetic Markers in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e841-e850.	1.1	148

#	ARTICLE	IF	CITATIONS
175	The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations. <i>Oncologist</i> , 2018, 23, 1266-1268.	1.9	2
176	PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 23-32.	1.1	21
177	Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing. <i>Human Mutation</i> , 2018, 39, 1442-1455.	1.1	5
178	Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 754-764.	1.2	9
179	Olaparib. <i>Recent Results in Cancer Research</i> , 2018, 211, 217-233.	1.8	60
180	PARP Inhibitors in Breast Cancer: Why, How, and When?. <i>Breast Care</i> , 2018, 13, 216-219.	0.8	4
181	Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02). <i>Frontiers in Oncology</i> , 2017, 7, 329.	1.3	11
182	Recent Advances in the Treatment of Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 227.	1.3	263
183	Should age impact breast cancer management in young women? Fine tuning of treatment guidelines. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	27
184	Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer. <i>Clinical Epigenetics</i> , 2018, 10, 88.	1.8	49
185	Therapeutic landscape in mutational triple negative breast cancer. <i>Molecular Cancer</i> , 2018, 17, 99.	7.9	70
186	Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark. <i>Annals of Surgical Oncology</i> , 2018, 25, 2925-2931.	0.7	53
187	4th ESO&EESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). <i>Annals of Oncology</i> , 2018, 29, 1634-1657.	0.6	891
188	Cardiovascular sequelae of breast cancer treatments: A review. <i>Current Problems in Cancer</i> , 2018, 42, 409-421.	1.0	4
189	Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878665.	1.4	105
190	Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. <i>Frontiers in Oncology</i> , 2018, 8, 92.	1.3	506
191	Advances in the Systemic Treatment of Triple-Negative Breast Cancer. <i>Current Oncology</i> , 2018, 25, 142-150.	0.9	241
192	Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 21-31.	1.1	32

#	ARTICLE	IF	CITATIONS
193	Managing Patient with Mutations in PALB2, CHEK2, or ATM. <i>Current Breast Cancer Reports</i> , 2018, 10, 74-82.	0.5	0
194	Predicting breast cancer therapeutic response. <i>Nature Medicine</i> , 2018, 24, 535-537.	15.2	6
195	Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1066.	3.4	146
196	Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. <i>Cancer</i> , 2018, 124, 3052-3065.	2.0	14
197	Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 1366-1376.	0.6	101
198	Patients' Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing. <i>Journal of Genetic Counseling</i> , 2018, 27, 1459-1472.	0.9	21
200	Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. <i>Annals of Oncology</i> , 2018, 29, 1939-1947.	0.6	107
201	Rucaparib: a novel PARP inhibitor for BRCA and advanced ovarian cancer. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 605-617.	2.0	26
202	Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 833-839.	1.3	16
203	Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. <i>Current Oncology Reports</i> , 2018, 20, 76.	1.8	72
204	Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 947-958.	1.1	5
205	Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 335-345.	2.7	23
206	Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. <i>Clinical Cancer Research</i> , 2018, 24, 6277-6287.	3.2	53
207	The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. <i>Cancer Management and Research</i> , 2018, Volume 10, 2553-2562.	0.9	28
208	A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-5.	0.2	4
209	Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. <i>New England Journal of Medicine</i> , 2018, 379, 753-763.	13.9	1,472
210	Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 347-348.	2.0	3
211	Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. <i>Annals of Translational Medicine</i> , 2018, 6, 163-163.	0.7	86

#	ARTICLE	IF	CITATIONS
212	BRCAness and prostate cancer: diagnostic and therapeutic considerations. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 488-498.	2.0	12
213	BRCA1/2 testing: therapeutic implications for breast cancer management. <i>British Journal of Cancer</i> , 2018, 119, 141-152.	2.9	142
214	Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network. <i>Scientific Reports</i> , 2018, 8, 8440.	1.6	23
215	Emerging therapeutic modalities of PARP inhibitors in breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 68, 62-68.	3.4	28
216	nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. <i>Annals of Oncology</i> , 2018, 29, 1763-1770.	0.6	94
217	Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?. <i>Current Oncology Reports</i> , 2018, 20, 63.	1.8	2
218	Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. <i>Annals of Oncology</i> , 2018, 29, 1948-1954.	0.6	60
219	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 29-39.	2.3	43
220	Whole-Genome Sequencing in Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a034579.	2.9	38
221	Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. <i>Genetics in Medicine</i> , 2019, 21, 213-223.	1.1	151
222	Broadening Criteria for BRCA1/2 Evaluation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 619.	3.8	9
223	Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial. <i>Future Oncology</i> , 2019, 15, 2327-2335.	1.1	7
224	Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan. <i>Journal of Clinical Medicine</i> , 2019, 8, 1170.	1.0	4
225	The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?. <i>Cancers</i> , 2019, 11, 1126.	1.7	90
226	Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 283-294.	1.1	34
228	<p>Triple-negative breast cancer: current perspective on the evolving therapeutic landscape</p>. <i>International Journal of Women's Health</i> , 2019, Volume 11, 431-437.	1.1	117
229	Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11). <i>Breast Cancer Research and Treatment</i> , 2019, 178, 367-377.	1.1	3
230	<i>VHL</i> Synthetic Lethality Signatures Uncovered by Genotype-Specific CRISPR-Cas9 Screens. <i>CRISPR Journal</i> , 2019, 2, 230-245.	1.4	8

#	ARTICLE	IF	CITATIONS
231	Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. <i>Annals of Oncology</i> , 2019, 30, 1541-1557.	0.6	464
232	Histone methyltransferase SMYD2: ubiquitous regulator of disease. <i>Clinical Epigenetics</i> , 2019, 11, 112.	1.8	50
233	Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2019, 9, 759.	1.3	18
234	PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms. <i>Journal of Investigative Medicine High Impact Case Reports</i> . 2019, 7, 232470961986498.	0.3	2
235	Hematologic toxicity in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers during chemotherapy: A retrospective matched cohort study. <i>Cancer Medicine</i> , 2019, 8, 5609-5618.	1.3	10
236	Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz005.	0.4	9
237	Factors associated with genetic testing in a cohort of breast cancer survivors. <i>Breast Journal</i> , 2019, 25, 1241-1244.	0.4	6
238	A Review of Local and Systemic Therapy in Breast Cancer. , 2019, , 637-690.		0
239	<p>Evidence to date: talazoparib in the treatment of breast cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5177-5187.	1.0	30
240	Overcoming Resistance to PARP Inhibition. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 161-189.	0.1	0
241	Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 151-159.	1.1	17
242	Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3390.	1.8	48
245	Psychosocial Effects of Multigene Panel Testing in the Context of Cancer Genomics. <i>Hastings Center Report</i> , 2019, 49, S44-S52.	0.7	15
246	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019, 571, 576-579.	13.7	295
247	Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC. <i>Case Reports in Oncology</i> , 2019, 12, 494-499.	0.3	5
248	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	1.7	160
249	Radiosensitivity Differences between EGFR Mutant and Wild-Type Lung Cancer Cells are Larger at Lower Doses. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3635.	1.8	22
250	Emerging Role of Genomics and Cell-Free DNA in Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 68.	1.3	9

#	ARTICLE	IF	CITATIONS
251	Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer. <i>Nature Communications</i> , 2019, 10, 2860.	5.8	18
252	Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 541-552.	1.5	14
253	Targeting DNA repair in breast cancer. <i>Breast</i> , 2019, 47, 33-42.	0.9	11
254	Matrix-producing Carcinoma as an Aggressive Triple-negative Breast Cancer: Clinicopathological Features and Response to Neoadjuvant Chemotherapy. <i>Anticancer Research</i> , 2019, 39, 3863-3869.	0.5	14
255	Treating HR+/HER2~ breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 549-559.	1.1	29
256	Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 163-173.	2.0	34
257	USP3 promotes breast cancer cell proliferation by deubiquitinating KLF5. <i>Journal of Biological Chemistry</i> , 2019, 294, 17837-17847.	1.6	49
258	PARP Inhibition in Cancer: An Update on Clinical Development. <i>Targeted Oncology</i> , 2019, 14, 657-679.	1.7	133
259	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 34.	2.3	55
260	Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 341.	0.8	39
261	Olaparib Quantification in Human Plasma for Clinical Purposes using High-Performance Liquid Chromatography with UV detector. <i>Analytical Chemistry Letters</i> , 2019, 9, 526-534.	0.4	3
262	Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. <i>Cancer Cell</i> , 2019, 36, 545-558.e7.	7.7	176
263	ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1899-1908.	1.9	52
264	Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1. <i>Current Breast Cancer Reports</i> , 2019, 11, 217-227.	0.5	7
265	Controversial issues in the neoadjuvant treatment of triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988258.	1.4	21
266	Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 119.	2.2	21
268	Cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer. <i>Personalized Medicine</i> , 2019, 16, 439-448.	0.8	7
269	Update Breast Cancer 2019 Part 5 "Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1090-1099.	0.8	16

#	ARTICLE	IF	CITATIONS
270	Germline mutation in DNA repair genes is associated with poor survival in BRCA 1/2-negative breast cancer patients. <i>Cancer Science</i> , 2019, 110, 3368-3374.	1.7	6
271	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3484-3492.	0.8	30
272	Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1049-1054.	0.6	14
273	Drug Sensitivity Prediction Models Reveal a Link between DNA Repair Defects and Poor Prognosis in HNSCC. <i>Cancer Research</i> , 2019, 79, 5597-5611.	0.4	28
274	Metronomic Oral Cyclophosphamide in 2 Heavily Pretreated Patients With Metastatic Castration-resistant Prostate Cancer With Homologous Recombination Deficiency (HRD): A Case Report. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 157-160.	0.9	3
275	The Voices of Nāmes: Women, Sex, and Marriage in Reformation Languedoc. <i>French History</i> , 2019, 33, 299-300.	0.1	0
276	Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge. <i>Cells</i> , 2019, 8, 957.	1.8	467
277	Breast Cancer Metastasis and Drug Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	38
278	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019, 120, 20-30.	1.3	75
279	Pathogenic Germline Variants in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1506.	3.4	10
280	Emerging Novel Therapeutics in Triple-Negative Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1152, 377-399.	0.8	23
282	Precision medicine for metastatic colorectal cancer: an evolving era. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 919-931.	1.4	34
283	Towards Circulating-Tumor DNA-Based Precision Medicine. <i>Journal of Clinical Medicine</i> , 2019, 8, 1365.	1.0	8
284	An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 787-801.	1.1	16
285	Inhibition of AKT Sensitizes Cancer Cells to Antineoplastic Drugs by Downregulating Flap Endonuclease 1. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2407-2420.	1.9	9
286	Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 858.	1.3	125
287	Available and emerging molecular markers in the clinical management of breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 919-928.	1.5	9
288	Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. <i>Cancers</i> , 2019, 11, 1334.	1.7	150

#	ARTICLE	IF	CITATIONS
289	Li-Fraumeni syndrome: not a straightforward diagnosis anymore—the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. <i>Breast Cancer Research</i> , 2019, 21, 107.	2.2	51
290	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. <i>Breast Care</i> , 2019, 14, 247-255.	0.8	32
291	Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. <i>PLoS ONE</i> , 2019, 14, e0222358.	1.1	35
292	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 698-712.	0.4	69
293	Prospects for combining immune checkpoint blockade with PARP inhibition. <i>Journal of Hematology and Oncology</i> , 2019, 12, 98.	6.9	92
294	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. <i>Breast Care</i> , 2019, 14, 224-245.	0.8	72
295	Positron-Emission Tomographic Imaging of a Fluorine 18—Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient—Derived Xenografts. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1743-1752.	0.5	14
296	Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1241-1256.	1.1	7
297	Breast cancer. <i>Nature Reviews Disease Primers</i> , 2019, 5, 66.	18.1	1,620
298	Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. <i>BMC Cancer</i> , 2019, 19, 901.	1.1	33
299	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	24
300	Breast Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 288.	3.8	2,785
301	Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study. <i>Gynecologic Oncology</i> , 2019, 153, 108-115.	0.6	15
302	A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. <i>European Journal of Cancer</i> , 2019, 109, 84-91.	1.3	19
303	Whole genome sequencing of breast cancer. <i>Apmis</i> , 2019, 127, 303-315.	0.9	23
304	PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF- β 2 in NMuMG Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 518.	1.8	30
305	Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 66-75.	2.0	24
306	Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). <i>Annals of Oncology</i> , 2019, 30, 365-373.	0.6	106

#	ARTICLE	IF	CITATIONS
307	Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets. <i>Molecular Cell</i> , 2019, 73, 885-899.e6.	4.5	137
308	OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. <i>Annals of Oncology</i> , 2019, 30, 558-566.	0.6	493
309	Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. <i>Cancer Discovery</i> , 2019, 9, 176-198.	7.7	778
310	MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. <i>Breast Cancer Research</i> , 2019, 21, 20.	2.2	52
311	Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 12-17.	0.9	7
312	Chlorambucil targets $\text{BRCA}1/2$ -deficient tumours and counteracts PARP inhibitor resistance. <i>EMBO Molecular Medicine</i> , 2019, 11, e9982.	3.3	26
313	Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984975.	1.4	70
314	Race, breast cancer, and prognosis: Where biology is queen?. <i>Cancer</i> , 2019, 125, 3104-3106.	2.0	1
315	Precision Medicine in Cancer Therapy. <i>Cancer Treatment and Research</i> , 2019, , .	0.2	4
316	Cardiotoxicities of Modern Treatments in Breast Cancer. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 34.	0.4	2
317	Update on Precision Medicine in Breast Cancer. <i>Cancer Treatment and Research</i> , 2019, 178, 45-80.	0.2	27
318	Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers. <i>Current Genetic Medicine Reports</i> , 2019, 7, 116-123.	1.9	0
319	Genomics-Enabled Precision Medicine for Cancer. <i>Cancer Treatment and Research</i> , 2019, 178, 137-169.	0.2	9
320	A decade of clinical development of PARP inhibitors in perspective. <i>Annals of Oncology</i> , 2019, 30, 1437-1447.	0.6	437
321	Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?. <i>ESMO Open</i> , 2019, 4, e000480.	2.0	47
322	Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 605-617.	0.8	28
323	DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. <i>Journal of Oncology</i> , 2019, 2019, 1-14.	0.6	18
324	Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 383-393.	1.1	12

#	ARTICLE	IF	CITATIONS
325	Hereditary Cancer Syndromesâ€”A Primer on Diagnosis and Management. Mayo Clinic Proceedings, 2019, 94, 1084-1098.	1.4	39
326	Adrenocortical carcinoma â€” towards genomics guided clinical care. Nature Reviews Endocrinology, 2019, 15, 548-560.	4.3	92
327	Systematic Analysis of Drug Vulnerabilities Conferred by Tumor Suppressor Loss. Cell Reports, 2019, 27, 3331-3344.e6.	2.9	19
330	Therapeutic innovations in breast cancer. Presse Medicale, 2019, 48, 1131-1137.	0.8	5
331	Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine, 2019, 381, 317-327.	13.9	1,521
332	State of art of advanced triple negative breast cancer. Breast Journal, 2019, 25, 967-970.	0.4	25
333	Update Breast Cancer 2019 Part 3 â€” Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2019, 79, 470-482.	0.8	26
334	Biomarkers for Breast Cancer Treatment. , 2019, , 115-124.		0
335	Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy. Expert Review of Anticancer Therapy, 2019, 19, 589-601.	1.1	8
336	Immune Checkpoint and Poly(ADPâ€”Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers. JAMA Oncology, 2019, 5, 1103.	3.4	2
337	Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncology, 2019, 5, 1132.	3.4	285
338	DNA double-strand break repair pathway choice - from basic biology to clinical exploitation. Cell Cycle, 2019, 18, 1423-1434.	1.3	20
339	Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. , 2019, 201, 94-102.		106
340	Alterations in DNA Damage Repair Genes in Primary Liver Cancer. Clinical Cancer Research, 2019, 25, 4701-4711.	3.2	74
341	The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone. International Journal of Cancer, 2019, 145, 2594-2596.	2.3	6
342	Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e8-e21.	1.8	22
343	The DNA Damaging Revolution: PARP Inhibitors and Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 185-195.	1.8	144
344	Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer. Scientific Reports, 2019, 9, 7509.	1.6	21

#	ARTICLE	IF	CITATIONS
345	<p>Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials</p>. Cancer Management and Research, 2019, Volume 11, 3061-3078.	0.9	10
346	Molecular Testing in Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e1-e7.	1.8	27
347	Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 61-74.	1.8	41
348	Trends in BRCA testing and socioeconomic deprivation. European Journal of Human Genetics, 2019, 27, 1351-1360.	1.4	6
349	Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Science Translational Medicine, 2019, 11, .	5.8	111
350	Recent advances in triple negative breast cancer: the immunotherapy era. BMC Medicine, 2019, 17, 90.	2.3	267
351	FANCM, RAD1, CHEK1 and TP53 act as BRCA-like tumor suppressors and are mutated in hereditary ovarian cancer. Cancer Genetics, 2019, 235-236, 57-64.	0.2	17
352	Deciphering the universe of genetic context-dependencies using mouse models of cancer. Current Opinion in Genetics and Development, 2019, 54, 97-104.	1.5	3
353	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncology, 2019, 15, 1951-1961.	1.1	58
354	Novel key genes in triple-negative breast cancer identified by weighted gene co-expression network analysis. Journal of Cellular Biochemistry, 2019, 120, 16900-16912.	1.2	27
355	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2019, 69, 280-304.	157.7	821
356	Next-generation sequencing of <i>BRCA1</i> and <i>BRCA2</i> genes for rapid detection of germline mutations in hereditary breast/ovarian cancer. PeerJ, 2019, 7, e6661.	0.9	21
357	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	2.3	76
358	PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discovery, 2019, 9, 722-737.	7.7	433
359	Luminal Metastatic Breast Cancer. Breast Care, 2019, 14, 99-101.	0.8	1
360	Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation. Npj Breast Cancer, 2019, 5, 14.	2.3	38
361	Targeting the PI3-kinase pathway in triple-negative breast cancer. Annals of Oncology, 2019, 30, 1051-1060.	0.6	180
362	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Journal of Clinical Oncology, 2019, 37, 2257-2269.	0.8	135

#	ARTICLE	IF	CITATIONS
363	Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. <i>JAMA Oncology</i> , 2019, 5, 887.	3.4	73
365	Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1012-1019.	1.3	2
366	Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?. <i>Stem Cell Investigation</i> , 2019, 6, 4-4.	1.3	1
367	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. <i>Biochemical Pharmacology</i> , 2019, 167, 133-148.	2.0	19
368	Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer. <i>International Journal of Biological Sciences</i> , 2019, 15, 962-972.	2.6	10
369	Targeting stem cells in the realm of drug-resistant breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 115-135.	1.0	33
370	Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 963-974.	1.1	8
371	Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics. <i>Ecancermedalscience</i> , 2019, 13, 904.	0.6	12
372	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591982771.	1.4	38
373	Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. <i>Cancer Cell</i> , 2019, 35, 428-440.e5.	7.7	571
374	Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4363-4374.	3.2	60
375	Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib. <i>Future Oncology</i> , 2019, 15, 1707-1715.	1.1	27
376	Lymph node metastasis in oral cancer is strongly associated with chromosomal instability and DNA repair defects. <i>International Journal of Cancer</i> , 2019, 145, 2568-2579.	2.3	33
377	Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. <i>Current Oncology Reports</i> , 2019, 21, 42.	1.8	15
378	A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e549-e552.	0.9	5
379	Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13037-13045.	1.2	9
380	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1383-1392.	0.8	9
381	Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1165-1174.	1.6	19

#	ARTICLE	IF	CITATIONS
382	Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world. <i>PLoS ONE</i> , 2019, 14, e0213746.	1.1	10
383	Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines. <i>Anticancer Research</i> , 2019, 39, 1813-1820.	0.5	14
384	Subcellular compartmentalization of NAD ⁺ and its role in cancer: A sereneNADE of metabolic melodies. , 2019, 200, 27-41.		53
385	Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. <i>Journal of Clinical Oncology</i> , 2019, 37, 1305-1315.	0.8	266
386	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> gene mutations in Chinese patients with high-risk breast cancer. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e677.	0.6	10
387	Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. <i>Journal of Hematology and Oncology</i> , 2019, 12, 38.	6.9	66
388	A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of <i>BRCA</i> -mutated breast cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 2321-2337.	0.9	83
389	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9008-9013.	3.3	108
390	Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1001-1011.	1.9	34
391	Prevalence of germline variants in inflammatory breast cancer. <i>Cancer</i> , 2019, 125, 2194-2202.	2.0	14
392	Poly(ADP-ribose)ylation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents. <i>EMBO Reports</i> , 2019, 20, .	2.0	31
393	PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. <i>Journal of Clinical Medicine</i> , 2019, 8, 435.	1.0	106
394	Genetics of Familial and Sporadic Pancreatic Cancer. <i>Gastroenterology</i> , 2019, 156, 2041-2055.	0.6	52
395	Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?. <i>Journal of Clinical Oncology</i> , 2019, 37, 453-460.	0.8	254
396	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. <i>Endocrine Connections</i> , 2019, 8, R10-R26.	0.8	33
397	Prognostic implications of a molecular classifier derived from whole-exome sequencing in nasopharyngeal carcinoma. <i>Cancer Medicine</i> , 2019, 8, 2705-2716.	1.3	13
398	Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with <i>BRCA</i> -mutated metastatic breast cancer treated in community oncology settings. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100121.	0.7	11
399	Triple-negative breast cancer: the reality in Chile and in Latin America. <i>Ecancermedicalscience</i> , 2019, 13, 893.	0.6	8

#	ARTICLE	IF	CITATIONS
400	Translational highlights in breast cancer research and treatment: recent developments with clinical impact. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 67-75.	0.9	16
401	Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines. <i>Breast Cancer</i> , 2019, 26, 510-519.	1.3	35
402	Patterns of Genomic Instability in Breast Cancer. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 198-211.	4.0	68
403	Pharmacotherapeutic options for patients with refractory breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 851-861.	0.9	3
404	PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 3759-3771.	3.2	265
405	The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. <i>Drugs</i> , 2019, 79, 381-400.	4.9	23
406	The 4717C>–G polymorphism in periplakin modulates sensitivity to EGFR inhibitors. <i>Scientific Reports</i> , 2019, 9, 2357.	1.6	5
407	Major clinical research advances in gynecologic cancer in 2018. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e18.	1.0	29
408	Therapeutic implications of germline genetic findings in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 386-396.	12.5	39
409	Development and implementation of precision therapies targeting base-excision DNA repair in BRCA1-associated tumors. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 11-25.	0.4	1
410	Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. <i>Scientific Reports</i> , 2019, 9, 1853.	1.6	167
411	How I treat metastatic triple-negative breast cancer. <i>ESMO Open</i> , 2019, 4, e000504.	2.0	59
412	In the literature: June 2019. <i>ESMO Open</i> , 2019, 4, e000547.	2.0	3
414	Genomics applied to the treatment of breast cancer. <i>Oncotarget</i> , 2019, 10, 4786-4801.	0.8	20
417	Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. <i>Clinical Cancer Research</i> , 2019, 25, 7517-7526.	3.2	34
418	Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review. <i>Asian Journal of Oncology</i> , 2019, 05, 01-18.	0.2	0
419	KISS1/KISS1R and Breast Cancer: Metastasis Promoter. <i>Seminars in Reproductive Medicine</i> , 2019, 37, 197-206.	0.5	11
420	Advances and perspectives of PARP inhibitors. <i>Experimental Hematology and Oncology</i> , 2019, 8, 29.	2.0	81

#	ARTICLE	IF	CITATIONS
422	Direct Ex Vivo Observation of Homologous Recombination Defect Reversal After DNA-Damaging Chemotherapy in Patients With Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	13
423	Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. <i>Breast Cancer Research</i> , 2019, 21, 143.	2.2	80
424	The Genetic Architecture of Gliomagenesisâ€™Genetic Risk Variants Linked to Specific Molecular Subtypes. <i>Cancers</i> , 2019, 11, 2001.	1.7	11
425	Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 247-255.	1.1	7
426	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. <i>Genome Biology</i> , 2019, 20, 253.	3.8	16
427	Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification. <i>Cancers</i> , 2019, 11, 1864.	1.7	5
428	Targeted Therapies for Triple-Negative Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 82.	1.3	237
429	Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. <i>Journal of Cancer</i> , 2019, 10, 5903-5914.	1.2	16
431	Immunotherapy in Triple-Negative Breast Cancer: Present and Future. <i>Current Breast Cancer Reports</i> , 2019, 11, 259-271.	0.5	22
433	Translational Highlights in Breast and Ovarian Cancer 2019 â€™ Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1309-1319.	0.8	11
434	Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. <i>Cancers</i> , 2019, 11, 1980.	1.7	29
435	BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. <i>Nature Communications</i> , 2019, 10, 5661.	5.8	45
436	Hype or hope? The strange case of platinum saltsâ€™™ renaissance in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 1005-1008.	1.1	2
437	Can we cure stage IV triple-negative breast carcinoma?. <i>Medicine (United States)</i> , 2019, 98, e17251.	0.4	5
438	Practical Cancer Genetics and Genomics in Womenâ€™™s Health. <i>Clinical Obstetrics and Gynecology</i> , 2019, 62, 687-699.	0.6	1
439	Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models. <i>PLoS ONE</i> , 2019, 14, e0225082.	1.1	9
440	Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis. <i>Npj Breast Cancer</i> , 2019, 5, 46.	2.3	26
441	Genome Sequencing during a Patientâ€™™s Journey through Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2145-2156.	13.9	50

#	ARTICLE	IF	CITATIONS
443	Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	0
444	Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	1.5	14
445	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants in a large, unselected breast cancer cohort. <i>International Journal of Cancer</i> , 2019, 144, 1195-1204.	2.3	31
446	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 74.	3.4	557
447	Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 505-514.	1.1	20
448	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO). <i>Clinical Cancer Research</i> , 2019, 25, 2717-2724.	3.2	102
449	Multiple Roles for Mono- and Poly(ADP-Ribose) in Regulating Stress Responses. <i>Trends in Genetics</i> , 2019, 35, 159-172.	2.9	26
450	Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again. <i>Journal of the American Heart Association</i> , 2019, 8, e011343.	1.6	50
451	Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. <i>Annals of Oncology</i> , 2019, 30, 405-411.	0.6	419
452	Atezolizumab for the treatment of triple-negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1-5.	1.9	78
453	Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. <i>Annals of Oncology</i> , 2019, 30, 397-404.	0.6	538
454	PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers. <i>Annual Review of Cancer Biology</i> , 2019, 3, 131-150.	2.3	63
455	Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. <i>Medicinal Research Reviews</i> , 2019, 39, 1205-1227.	5.0	21
456	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer: an European consensus statement and expert recommendations. <i>European Journal of Cancer</i> , 2019, 106, 54-60.	1.3	25
457	Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 171-182.	2.0	93
458	Oncogenic activity of poly (ADP-ribose) glycohydrolase. <i>Oncogene</i> , 2019, 38, 2177-2191.	2.6	21
459	Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 627-637.	1.1	12
460	Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 855-860.	2.0	13

#	ARTICLE	IF	CITATIONS
461	Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. <i>British Journal of Cancer</i> , 2019, 120, 279-285.	2.9	17
462	SEOM clinical guidelines in advanced and recurrent breast cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 31-45.	1.2	14
463	Population and breast cancer patientsâ€™ analysis reveals the diversity of genomic variation of the BRCA genes in the Mexican population. <i>Human Genomics</i> , 2019, 13, 3.	1.4	16
464	Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 385-395.	1.1	15
465	State-of-the-art strategies for targeting the DNA damage response in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 81-104.	12.5	736
466	Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 29-42.	1.1	11
467	PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. <i>Journal of Geriatric Oncology</i> , 2019, 10, 337-345.	0.5	25
468	Systemic Treatment of HER2-Negative Metastatic Breast Cancer. , 2019, , 483-508.		0
469	Foundations and Application of Precision Medicine. , 2019, , 21-45.		0
470	Early-onset colorectal cancer in young individuals. <i>Molecular Oncology</i> , 2019, 13, 109-131.	2.1	365
471	Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. <i>Chemical Communications</i> , 2019, 55, 369-372.	2.2	114
472	A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer. <i>Cancer Medicine</i> , 2019, 8, 383-399.	1.3	14
473	BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy. <i>International Journal of Cancer</i> , 2019, 144, 755-766.	2.3	54
474	CRISPR/Cas9 for cancer research and therapy. <i>Seminars in Cancer Biology</i> , 2019, 55, 106-119.	4.3	206
475	Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 229-241.	2.3	51
476	Prevalence and clinical impact of <i>TP53</i> germline mutations in Chinese women with breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 487-495.	2.3	16
477	SPTBN1 and cancer, which links?. <i>Journal of Cellular Physiology</i> , 2020, 235, 17-25.	2.0	25
478	Targeted therapy for breast cancer in older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 380-388.	0.5	9

#	ARTICLE	IF	CITATIONS
479	Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 602-613.	1.9	20
480	Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1082-1115.	2.3	88
481	Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers. <i>Cancer</i> , 2020, 126, 271-280.	2.0	74
482	Untapped "omics", the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 287-300.	1.1	33
483	Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. <i>Annals of Palliative Medicine</i> , 2020, 9, 1296-1306.	0.5	5
484	Tumor Liquid Biopsies. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	11
485	Genetic Factors. , 2020, , 180-208.e11.		4
486	Rate of BRCA mutation in patients tested under NCCN genetic testing criteria. <i>American Journal of Surgery</i> , 2020, 219, 145-149.	0.9	13
487	Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. <i>Journal of Clinical Oncology</i> , 2020, 38, 388-394.	0.8	151
488	Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2~ Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 1-11.	1.1	20
489	Metastatic Conditioning of Myeloid Cells at a Subcutaneous Synthetic Niche Reflects Disease Progression and Predicts Therapeutic Outcomes. <i>Cancer Research</i> , 2020, 80, 602-612.	0.4	28
490	Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). <i>Investigational New Drugs</i> , 2020, 38, 1117-1128.	1.2	10
491	Cancer Genetic Counseling—Current Practice and Future Challenges. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036541.	2.9	9
492	Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). <i>Investigational New Drugs</i> , 2020, 38, 1096-1107.	1.2	11
493	BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies. <i>Annals of Laboratory Medicine</i> , 2020, 40, 114-121.	1.2	67
494	Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections. <i>Clinical Breast Cancer</i> , 2020, 20, 152-159.	1.1	9
495	Immunotherapy for the Treatment of Breast Cancer: Emerging New Data. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 321-328.	1.0	25
496	An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor. <i>Oncologist</i> , 2020, 25, e60-e67.	1.9	9

#	ARTICLE	IF	CITATIONS
497	ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. <i>Cancer Letters</i> , 2020, 473, 148-155.	3.2	31
498	PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 718-729.	0.5	13
499	AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer. <i>BMC Cancer</i> , 2020, 20, 18.	1.1	19
500	Expression of tumor-associated antigens in breast cancer subtypes. <i>Breast</i> , 2020, 49, 202-209.	0.9	24
501	Triple negative breast cancer: A thorough review of biomarkers. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102855.	2.0	153
502	Understanding genetic determinants of resistance to immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2020, 65, 123-139.	4.3	9
503	Bone Metastasis: Current State of Play. <i>Translational Oncology</i> , 2020, 13, 308-320.	1.7	30
504	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	1.1	5
505	Precision Medicine and Targeted Therapies in Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 51-62.	0.6	32
506	Metallointercalator [Ru(dppz)2(PIP)]2+ Renders BRCA Wild-Type Triple-Negative Breast Cancer Cells Hypersensitive to PARP Inhibition. <i>ACS Chemical Biology</i> , 2020, 15, 378-387.	1.6	12
507	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. <i>Translational Oncology</i> , 2020, 13, 410-422.	1.7	52
508	Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer. <i>JCO Oncology Practice</i> , 2020, 16, e37-e55.	1.4	16
509	Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). <i>Genetics in Medicine</i> , 2020, 22, 681-685.	1.1	20
510	Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. <i>British Journal of Cancer</i> , 2020, 122, 483-490.	2.9	8
511	Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?. , 2020, 207, 107450.		101
512	Germline genetic testing for breast cancer: which patients? What genes?. <i>Genetics in Medicine</i> , 2020, 22, 698-700.	1.1	3
513	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. <i>Clinical Cancer Research</i> , 2020, 26, 1372-1384.	3.2	66
514	Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. <i>Drugs</i> , 2020, 80, 131-146.	4.9	10

#	ARTICLE	IF	CITATIONS
515	Comprehensive profiling of <i>BRCA1</i> and <i>BRCA2</i> variants in breast and ovarian cancer in Chinese patients. <i>Human Mutation</i> , 2020, 41, 696-708.	1.1	21
516	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. <i>Journal of Clinical Oncology</i> , 2020, 38, 406-414.	0.8	60
517	Delving into PARP inhibition from bench to bedside and back. , 2020, 206, 107446.		11
518	P5 eHealth: An Agenda for the Health Technologies of the Future. , 2020, , .		21
519	Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 273-281.	0.8	4
520	Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy. <i>Case Reports in Oncology</i> , 2020, 12, 814-819.	0.3	0
521	Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020. <i>Breast Journal</i> , 2020, 26, 69-80.	0.4	31
522	Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 359-367.	1.1	36
523	An Emerging Regulatory Role for the Tumor Microenvironment in the DNA Damage Response to Double-Strand Breaks. <i>Molecular Cancer Research</i> , 2020, 18, 185-193.	1.5	28
524	DNA damage repair functions and targeted treatment in breast cancer. <i>Breast Cancer</i> , 2020, 27, 355-362.	1.3	15
525	Establishing a Framework for the Clinical Translation of Germline Findings in Precision Oncology. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa045.	1.4	6
526	Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 130.	6.9	166
527	Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome. <i>JCO Precision Oncology</i> , 2020, 4, 841-847.	1.5	4
528	Clinical assays for assessment of homologous recombination DNA repair deficiency. <i>Gynecologic Oncology</i> , 2020, 159, 887-898.	0.6	70
529	New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 578095.	1.3	36
530	The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome. <i>Pharmacological Research</i> , 2020, 161, 105249.	3.1	13
531	Can we cure oligometastatic disease? A practical point of view. <i>Current Opinion in Oncology</i> , 2020, 32, 568-574.	1.1	5
532	<p></p>Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9375-9387.	0.9	16

#	ARTICLE	IF	CITATIONS
533	Survival benefits of PARP inhibitors in advanced breast cancer: aÂmirage?. <i>Annals of Oncology</i> , 2020, 31, 1432-1434.	0.6	4
536	Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. <i>Life Sciences</i> , 2020, 261, 118434.	2.0	23
537	Targeting the intrinsically disordered architectural High Mobility Group A (HMGA) oncoproteins in breast cancer: learning from the past to design future strategies. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 953-969.	1.5	7
538	Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results. <i>Current Opinion in Oncology</i> , 2020, 32, 585-593.	1.1	3
539	Causal Bayesian gene networks associated with bone, brain and lung metastasis of breast cancer. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 657-674.	1.7	22
540	Combined Radiotherapy and New Systemic Therapies â€œ Have We Moved Beyond Palliation?. <i>Clinical Oncology</i> , 2020, 32, 758-765.	0.6	6
541	CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 61-66.	0.9	15
542	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. <i>Npj Breast Cancer</i> , 2020, 6, 54.	2.3	181
543	The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. <i>Cancer Biology and Medicine</i> , 2020, 17, 1002-1013.	1.4	18
544	CIC-3/SBK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma. <i>Cell Death and Disease</i> , 2020, 11, 898.	2.7	13
545	Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants. <i>Communications Biology</i> , 2020, 3, 578.	2.0	20
546	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020, 31, 1623-1649.	0.6	761
547	Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. <i>Oncologist</i> , 2020, 25, 943-953.	1.9	19
550	Cancer cell-selective modulation of mitochondrial respiration and metabolism by potent organogold(<sc>iii</sc>) dithiocarbamates. <i>Chemical Science</i> , 2020, 11, 10465-10482.	3.7	37
551	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 1491-1505.	0.6	658
552	The DNA damaging revolution. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103117.	2.0	9
553	Drug screening model meets cancer organoid technology. <i>Translational Oncology</i> , 2020, 13, 100840.	1.7	38
554	ABC4 Consensus: First Latin American Meetingâ€™ Assessment, Comments, and Application of Its Recommendations. <i>JCO Global Oncology</i> , 2020, 6, 819-827.	0.8	2

#	ARTICLE	IF	CITATIONS
555	Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma. <i>Cancers</i> , 2020, 12, 1832.	1.7	30
556	Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology. <i>JCO Global Oncology</i> , 2020, 6, 991-1008.	0.8	9
559	Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations. <i>Frontiers in Oncology</i> , 2020, 10, 553080.	1.3	14
560	Successful olaparib desensitization using a novel one-day protocol. <i>Allergy, Asthma and Clinical Immunology</i> , 2020, 16, 100.	0.9	1
561	Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer. <i>JAMA Network Open</i> , 2020, 3, e2026921.	2.8	61
562	Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?. <i>ESMO Open</i> , 2020, 5, e001112.	2.0	30
563	Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort. <i>Scientific Reports</i> , 2020, 10, 20223.	1.6	15
564	Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA1/2 Germline Mutations: Report of Ten Cases and a Literature Review. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11637-11644.	1.0	7
565	Health Care Disparities and Demand for Expanding Hereditary Breast Cancer Screening Guidelines in African Americans. <i>Clinical Breast Cancer</i> , 2021, 21, e220-e227.	1.1	7
566	Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy. <i>Molecules</i> , 2020, 25, 5686.	1.7	19
567	Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9034.	1.8	5
568	DNA Damaged Induced Cell Death in Oocytes. <i>Molecules</i> , 2020, 25, 5714.	1.7	30
569	Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. <i>Nature Communications</i> , 2020, 11, 5679.	5.8	41
570	Update Breast Cancer 2020 Part 4 "Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1115-1122.	0.8	11
571	Sarcopenia in aging, obesity, and cancer. <i>Translational Cancer Research</i> , 2020, 9, 5760-5771.	0.4	33
572	Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology. <i>Frontiers in Oncology</i> , 2020, 10, 611127.	1.3	0
573	Combinatorial Therapy of High Dose Vitamin C and PARP Inhibitors in DNA Repair Deficiency: A Series of 8 Patients. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542096981.	0.8	8
575	Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3528-3537.	0.8	64

#	ARTICLE	IF	CITATIONS
576	Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant. <i>Npj Breast Cancer</i> , 2020, 6, 31.	2.3	13
577	Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 265-275.	1.1	22
578	The emerging role of PARP inhibitors in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 715-726.	1.1	12
579	Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment. <i>BMC Cancer</i> , 2020, 20, 748.	1.1	36
581	Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 901-910.	1.9	18
582	Clinical implications of breast cancer tumor genomic testing. <i>Breast Journal</i> , 2020, 26, 1565-1571.	0.4	3
583	The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy—Current progress and future direction. <i>European Journal of Medicinal Chemistry</i> , 2020, 203, 112570.	2.6	45
584	Homologous repair deficiency score for identifying breast cancers with defective DNA damage response. <i>Scientific Reports</i> , 2020, 10, 12506.	1.6	23
585	BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis. <i>Cancer Research</i> , 2020, 80, 4601-4609.	0.4	30
586	Effects of Cancer Stem Cells in Triple-Negative Breast Cancer and Brain Metastasis: Challenges and Solutions. <i>Cancers</i> , 2020, 12, 2122.	1.7	18
587	Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. <i>Lancet Oncology</i> , The, 2020, 21, 1155-1164.	5.1	274
588	Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). <i>Cancer</i> , 2020, 126, 3867-3882.	2.0	15
589	Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 697-704.	1.1	3
590	Current and emerging biologic therapies for triple negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 591-602.	1.4	11
591	Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy. <i>Annals of Palliative Medicine</i> , 2020, 9, 3018-3027.	0.5	2
592	Novel targeted therapies for metastatic breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 907-907.	0.7	10
593	Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. <i>Breast Cancer Research</i> , 2020, 22, 114.	2.2	25
594	Synthetic Lethality through the Lens of Medicinal Chemistry. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14151-14183.	2.9	31

#	ARTICLE	IF	CITATIONS
595	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	0.8	276
596	The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. <i>Cancers</i> , 2020, 12, 3129.	1.7	29
597	Do Olive and Fish Oils of the Mediterranean Diet Have a Role in Triple Negative Breast Cancer Prevention and Therapy? An Exploration of Evidence in Cells and Animal Models. <i>Frontiers in Nutrition</i> , 2020, 7, 571455.	1.6	15
599	Development of circulating tumour DNA analysis for gastrointestinal cancers. <i>ESMO Open</i> , 2020, 5, e000600.	2.0	20
600	The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1199-1208.	1.9	17
601	Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. <i>Breast Cancer</i> , 2021, 28, 1167-1180.	1.3	118
602	Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 689-698.	1.1	4
603	Poly(ADP-ribose) polymerase inhibition: past, present and future. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 711-736.	21.5	275
604	Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. <i>Journal of Hematology and Oncology</i> , 2020, 13, 118.	6.9	95
605	Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2020, 13, 904-910.	0.3	6
606	PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. <i>Medicines (Basel, Switzerland)</i> , 2020, 7, 54.	0.7	21
607	Genomic Signatures in Luminal Breast Cancer. <i>Breast Care</i> , 2020, 15, 355-365.	0.8	20
609	Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation. <i>Medicine (United States)</i> , 2020, 99, e22312.	0.4	5
610	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 44.	2.3	5
611	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2345-2357.	13.9	440
612	The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1608-1618.	1.2	4
613	Synthesis and Chemistry of 1,2,3-Benzothiadiazine 1,1-Dioxide Derivatives: A Comprehensive Overview. <i>Chemistry</i> , 2020, 2, 674-690.	0.9	4
614	Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors” proceedings from breast cancer expert group meeting. <i>Chinese Clinical Oncology</i> , 2020, 9, 61-61.	0.4	4

#	ARTICLE	IF	CITATIONS
615	miR-452 Reverses Abnormal Glycosylation Modification of ER \pm and Estrogen Resistance in TNBC (Triple-Negative Breast Cancer) Through Targeting UGT1A1. <i>Frontiers in Oncology</i> , 2020, 10, 1509.	1.3	10
616	BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?. <i>Lancet Oncology</i> , The, 2020, 21, 1254-1255.	5.1	1
617	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1269-1282.	5.1	207
618	Strategies to enhance identification of hereditary breast cancer gene carriers. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 861-865.	1.5	1
619	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. <i>Cancers</i> , 2020, 12, 2392.	1.7	171
620	Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degradator of PARP1 for Treating Cancers. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11012-11033.	2.9	43
621	Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center. <i>Cancer Reports</i> , 2020, 3, e1287.	0.6	1
622	PARP inhibition in treatment of pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 939-945.	1.1	14
624	Somatic Testing and Germline Genetic Status: Implications for Cancer Treatment Decisions and Genetic Counseling. <i>Current Genetic Medicine Reports</i> , 2020, 8, 109-119.	1.9	0
625	Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. <i>Drugs</i> , 2020, 80, 1685-1697.	4.9	72
626	Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1012-1024.	1.5	11
627	PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 564601.	1.8	315
629	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. <i>EBioMedicine</i> , 2020, 59, 102923.	2.7	22
630	<p>Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 227-238.	0.4	8
631	Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 1415.	1.3	31
632	Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China. <i>Breast</i> , 2020, 53, 172-180.	0.9	13
633	Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma. <i>EBioMedicine</i> , 2020, 59, 102971.	2.7	41
634	Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. <i>Breast Care</i> , 2020, 15, 608-618.	0.8	8

#	ARTICLE	IF	CITATIONS
635	Germline BRCA1 mutated esophageal squamous cell carcinoma. <i>Rare Tumors</i> , 2020, 12, 203636132097221.	0.3	3
636	Utility of Circulating Tumor DNA in Different Clinical Scenarios of Breast Cancer. <i>Cancers</i> , 2020, 12, 3797.	1.7	4
637	Impact of variants in ATP-binding cassette transporters on breast cancer treatment. <i>Pharmacogenomics</i> , 2020, 21, 1299-1310.	0.6	9
638	Molecular Features and Clinical Management of Hereditary Gynecological Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9504.	1.8	13
639	Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2557-2570.	13.9	146
640	Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIRO2-Lung Trial. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100068.	0.6	10
641	Breast cancer in global health: beyond diversity and inequality. <i>International Journal of Surgery Global Health</i> , 2020, 3, e32-e32.	0.2	4
642	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. <i>JCO Precision Oncology</i> , 2020, 4, 1350-1360.	1.5	18
643	Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. <i>Cancers</i> , 2020, 12, 3256.	1.7	8
644	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020, 3, e2021692.	2.8	70
645	Characteristics and Prognosis of Triple-Negative Breast Cancer Patients: a Croatian Single Institution Retrospective Cohort Study. <i>Acta Clinica Croatica</i> , 2020, 59, 97-108.	0.1	8
646	Breast Cancer and BRCA1 and BRCA2 Pathogenic Variants. , 2020, , .		0
648	Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 884-892.	3.0	21
649	Management of early breast cancer in patients bearing germline BRCA mutations. <i>Seminars in Oncology</i> , 2020, 47, 243-248.	0.8	3
650	Targeted Molecular Therapy in Palliative Cancer Management. , 2020, 5, .		1
651	Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e2019452.	2.8	76
652	Drug Repurposing for Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2020, 10, 200.	1.1	29
653	Which path to follow? Utilizing proteomics to improve therapy choices for breast cancer patients. <i>Expert Review of Proteomics</i> , 2020, 17, 187-190.	1.3	2

#	ARTICLE	IF	CITATIONS
654	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4135-4142.	3.2	95
655	<i>EZH2</i>-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress. <i>Cancer Discovery</i> , 2020, 10, 998-1017.	7.7	29
656	Implications of BRCA Germline Mutations on Breast Cancer Medical Treatment. <i>Current Breast Cancer Reports</i> , 2020, 12, 59-65.	0.5	0
657	What’s the Price? Toxicities of Targeted Therapies in Breast Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 55-70.	1.8	13
658	Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies. <i>Cancer</i> , 2020, 126, 3209-3218.	2.0	23
659	Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. <i>International Journal of Cancer</i> , 2020, 147, 2658-2668.	2.3	13
660	Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG). <i>Genetics in Medicine</i> , 2020, 22, 1142-1148.	1.1	59
661	Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 628.	1.3	34
662	Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. <i>Scientific Reports</i> , 2020, 10, 8753.	1.6	20
663	Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. <i>Cancer Medicine</i> , 2020, 9, 5035-5050.	1.3	8
664	Successful pregnancy in a cancer patient previously cured of a gestational trophoblastic tumor by immunotherapy. <i>Annals of Oncology</i> , 2020, 31, 823-825.	0.6	9
665	Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA. <i>Annals of Oncology</i> , 2020, 31, 822-823.	0.6	24
666	Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. <i>Oncologist</i> , 2020, 25, e1158-e1169.	1.9	11
667	Disparities in Genetic Testing and Care Among Black Women with Hereditary Breast Cancer. <i>Current Breast Cancer Reports</i> , 2020, 12, 125-131.	0.5	29
668	Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 491-502.	1.1	2
669	Trap and kill strategy for non-BRCA mutant pancreatic cancer by co-delivery of olaparib and JQ1 with plectin-1 targeting peptide nanoparticles. <i>Nano Today</i> , 2020, 33, 100877.	6.2	18
670	Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. <i>Nature Communications</i> , 2020, 11, 2662.	5.8	157
671	Genomics-guided pre-clinical development of cancer therapies. <i>Nature Cancer</i> , 2020, 1, 482-492.	5.7	23

#	ARTICLE	IF	CITATIONS
672	Atezolizumab in the treatment of metastatic triple-negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 981-989.	1.4	20
673	Integrating Genetic and Genomic Testing Into Oncology Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e259-e263.	1.8	6
674	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020, 12, 1319.	1.7	10
675	PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?. <i>Cancers</i> , 2020, 12, 1378.	1.7	29
676	The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 102988.	2.0	25
677	Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer. <i>Current Opinion in Urology</i> , 2020, 30, 519-526.	0.9	15
678	Genetic Testing and Screening Recommendations for Patients with Hereditary Breast Cancer. <i>Radiographics</i> , 2020, 40, 913-936.	1.4	13
679	A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib. <i>Anticancer Research</i> , 2020, 40, 2509-2514.	0.5	8
680	Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 570.	1.3	127
681	Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience. <i>Cancers</i> , 2020, 12, 1306.	1.7	0
682	HRness in Breast and Ovarian Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3850.	1.8	14
683	A review on methods for diagnosis of breast cancer cells and tissues. <i>Cell Proliferation</i> , 2020, 53, e12822.	2.4	87
684	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. <i>Cancers</i> , 2020, 12, 1502.	1.7	145
685	Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer. <i>Pharmaceutics</i> , 2020, 12, 524.	2.0	22
686	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non- <i>BRCA1/2</i> -Mutant Cancers. <i>Cancer Discovery</i> , 2020, 10, 1528-1543.	7.7	82
687	PARP inhibitor resistance: the underlying mechanisms and clinical implications. <i>Molecular Cancer</i> , 2020, 19, 107.	7.9	235
688	Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4852-4862.	3.2	12
689	Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges. <i>Cancers</i> , 2020, 12, 1404.	1.7	78

#	ARTICLE	IF	CITATIONS
690	Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. <i>BMC Cancer</i> , 2020, 20, 507.	1.1	48
691	Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3895.	1.8	4
692	NAD metabolism in aging and cancer. <i>Experimental Biology and Medicine</i> , 2020, 245, 1594-1614.	1.1	17
693	ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738. <i>Genome Instability & Disease</i> , 2020, 1, 197-205.	0.5	9
694	Prior Treatment Time Affects Survival Outcomes in Metastatic Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 500-513.	1.0	7
695	Comprehensive analysis of CTLA-4 in the tumor immune microenvironment of 33 cancer types. <i>International Immunopharmacology</i> , 2020, 85, 106633.	1.7	14
696	Clinical outcome of adjuvant radiotherapy for squamous cell carcinoma of the breast; a multicenter retrospective cohort study. <i>Breast</i> , 2020, 52, 88-94.	0.9	6
697	Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 1315-1325.	1.5	8
698	A Population-Based Analysis of Breast Cancer Incidence and Survival by Subtype in Ontario Women. <i>Current Oncology</i> , 2020, 27, 191-198.	0.9	20
699	Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	0.6	11
700	Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features. <i>Breast Care</i> , 2020, 15, 208-216.	0.8	6
702	Panel Testing for Hereditary Breast Cancer: More or Less?. <i>Current Breast Cancer Reports</i> , 2020, 12, 45-50.	0.5	0
703	Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience. <i>Oncologist</i> , 2020, 25, e1996-e2005.	1.9	21
704	Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. <i>Future Oncology</i> , 2020, 16, 1751-1766.	1.1	20
705	How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989753.	1.4	8
706	The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. <i>Cell and Bioscience</i> , 2020, 10, 35.	2.1	57
707	Hormone Receptorâ€“Positive/Human Epidermal Growth Receptor 2â€“Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents. <i>Oncologist</i> , 2020, 25, e900-e908.	1.9	15
708	International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus â€“ Assessment by a German Group of Experts. <i>Breast Care</i> , 2020, 15, 82-95.	0.8	25

#	ARTICLE	IF	CITATIONS
709	Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil. <i>JCO Global Oncology</i> , 2020, 6, 439-452.	0.8	25
710	Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a/5p/BRCA1 signaling. <i>FASEB Journal</i> , 2020, 34, 5877-5891.	0.2	9
711	Update Breast Cancer 2020 Part 1 "Early Breast Cancer: Consolidation of Knowledge About Known Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 277-287.	0.8	16
712	ATM-Deficient Cancers Provide New Opportunities for Precision Oncology. <i>Cancers</i> , 2020, 12, 687.	1.7	76
713	Molecular natural history of breast cancer: Leveraging transcriptomics to predict breast cancer progression and aggressiveness. <i>Cancer Medicine</i> , 2020, 9, 3551-3562.	1.3	8
714	Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm. <i>Clinical and Translational Oncology</i> , 2020, 22, 1698-1709.	1.2	9
715	Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa002.	1.4	8
716	Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090909.	1.4	14
717	Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. <i>Drugs in R and D</i> , 2020, 20, 55-73.	1.1	84
718	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 18.	1.3	72
719	Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. <i>Cancers</i> , 2020, 12, 819.	1.7	61
720	NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer. <i>Nature Communications</i> , 2020, 11, 1669.	5.8	93
721	Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1807-1818.	1.1	14
722	Tickling PARPs into serine action. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 310-312.	3.6	5
723	PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. <i>Molecular Cancer</i> , 2020, 19, 49.	7.9	145
724	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1409-1418.	0.8	64
725	2. Therapie des metastasierten Mammakarzinoms. , 2020, , 71-120.		0
726	4. Supportivtherapie. , 2020, , 127-216.		0

#	ARTICLE	IF	CITATIONS
727	Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 10459.	1.6	32
728	Optimal Systemic Treatment for Early Triple-Negative Breast Cancer. <i>Breast Care</i> , 2020, 15, 217-226.	0.8	19
729	The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. <i>Human Reproduction</i> , 2020, 35, 1864-1874.	0.4	36
730	Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 13.	0.6	0
731	Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier. <i>Breast Journal</i> , 2020, 26, 1506-1512.	0.4	1
732	Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status. <i>Cancers</i> , 2020, 12, 1769.	1.7	14
733	Homologous recombination deficiency in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 375-379.	0.3	2
735	Inflammasomes and Proteostasis Novel Molecular Mechanisms Associated With Atrial Fibrillation. <i>Circulation Research</i> , 2020, 127, 73-90.	2.0	60
736	Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. <i>Cancer Treatment Reviews</i> , 2020, 88, 102064.	3.4	41
737	A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. <i>Journal of Controlled Release</i> , 2020, 326, 628-647.	4.8	149
738	Pharmacological methods to transcriptionally modulate double-strand break DNA repair. <i>International Review of Cell and Molecular Biology</i> , 2020, 354, 187-213.	1.6	8
739	The evolving management of metastatic triple negative breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 229-237.	0.8	28
740	Early stage triple negative breast cancer: Management and future directions. <i>Seminars in Oncology</i> , 2020, 47, 201-208.	0.8	23
741	ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 588-600.	0.8	1
742	Tackling the Biological Diversity in Early Triple-Negative Breast Cancer. <i>Breast Care</i> , 2020, 15, 205-207.	0.8	2
743	PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasis. <i>Genes and Development</i> , 2020, 34, 302-320.	2.7	91
745	PARP and PARG inhibitors in cancer treatment. <i>Genes and Development</i> , 2020, 34, 360-394.	2.7	360
746	Applications of Functional Genomics for Drug Discovery. <i>SLAS Discovery</i> , 2020, 25, 823-842.	1.4	6

#	ARTICLE	IF	CITATIONS
747	Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 3117-3127.	1.6	12
748	Metastatic Thymoma Harboring a Deleterious <i>BRCA2</i> Mutation Derives Durable Clinical Benefit from Olaparib. <i>Oncologist</i> , 2020, 25, 301-305.	1.9	9
749	Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	7
750	PARP inhibitors: a tsunami of indications in different malignancies. <i>Pharmacogenomics</i> , 2020, 21, 221-230.	0.6	16
751	BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. <i>Diagnostics</i> , 2020, 10, 119.	1.3	6
752	Group plus individual pre-test genetic counselling sessions for hereditary cancer shorten provider time and improve patient satisfaction. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 3.	0.6	11
753	A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity. <i>Nature Communications</i> , 2020, 11, 822.	5.8	62
754	Management of Male Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1849-1863.	0.8	122
755	Pharmacological issues concerning olaparib capsule and tablet formulations in treating ovarian cancer: Are they really the same drug?. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 967-971.	0.5	3
756	Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , 2020, 12, 17.	3.6	20
757	OlympiAD trial: moving to a next level of treatment for patients with BRCA mutation and her2-negative metastatic breast cancer. <i>Annals of Palliative Medicine</i> , 2020, 9, 510-511.	0.5	1
758	Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors. <i>Genetics in Medicine</i> , 2020, 22, 1088-1093.	1.1	10
759	Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer. <i>Cancer Science</i> , 2020, 111, 1375-1384.	1.7	35
760	Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 59-65.	0.4	13
761	The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication. <i>Nature Reviews Molecular Cell Biology</i> , 2020, 21, 284-299.	16.1	199
762	The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1231-1241.	3.0	61
763	Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. <i>Journal of Cellular Biochemistry</i> , 2020, 210, 1075-1088.		66
764	Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. <i>Annals of Oncology</i> , 2020, 31, 590-598.	0.6	108

#	ARTICLE	IF	CITATIONS
765	The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1). <i>Breast Cancer Research and Treatment</i> , 2020, 180, 511-514.	1.1	6
766	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <i><i>BRCA</i></i> Mutations among Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2546-2555.	3.2	33
767	Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 687-699.	0.9	41
768	Establishment and Characterization of a <i>Brca1</i> ^{+/+} , <i>p53</i> ^{+/+} Mouse Mammary Tumor Cell Line. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1185.	1.8	10
769	Systematic misclassification of missense variants in BRCA1 and BRCA2 <i>â€œcoldspotsâ€œ</i> . <i>Genetics in Medicine</i> , 2020, 22, 825-830.	1.1	32
770	Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy. <i>Future Oncology</i> , 2020, 16, 75-80.	1.1	11
771	Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer. <i>High-Throughput</i> , 2020, 9, 1.	4.4	22
773	CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. <i>Leukemia</i> , 2020, 34, 1599-1612.	3.3	21
774	A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. <i>Investigational New Drugs</i> , 2020, 38, 1400-1410.	1.2	25
775	Effects of <i><i>BRCA</i></i> Germline Mutations on Triple-Negative Breast Cancer Prognosis. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	30
776	Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989754.	1.4	18
777	Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers. <i>Genetics in Medicine</i> , 2020, 22, 831-839.	1.1	19
778	Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, e196400.	3.4	32
779	Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. <i>Scientific Reports</i> , 2020, 10, 7073.	1.6	57
780	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2091-2102.	13.9	1,327
781	DNA Damage, an Innocent Bystander in Atrial Fibrillation and Other Cardiovascular Diseases?. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 67.	1.1	11
782	Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00149.	1.3	8
783	The Landscape of Targeted Therapies in TNBC. <i>Cancers</i> , 2020, 12, 916.	1.7	232

#	ARTICLE	IF	CITATIONS
784	Molecular profiling in breast cancerâ€”ready for clinical routine?. Memo - Magazine of European Medical Oncology, 2020, 13, 445-449.	0.3	7
785	ESOâ€”ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Annals of Oncology, 2020, 31, 674-696.	0.6	172
786	Biologic therapy for advanced breast cancer: recent advances and future directions. Expert Opinion on Biological Therapy, 2020, 20, 1009-1024.	1.4	23
787	Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers, 2020, 12, 972.	1.7	14
788	Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1. Cells, 2020, 9, 941.	1.8	3
789	Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation. International Journal of Molecular Sciences, 2020, 21, 2691.	1.8	22
790	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with<i>AKT1</i>E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 3947-3957.	3.2	54
791	Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1. Chinese Medical Journal, 2020, 133, 853-862.	0.9	21
792	Spectrum of <i>PALB2</i> germline mutations and characteristics of <i>PALB2</i>-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by nextâ€”generation sequencing. Cancer, 2020, 126, 3202-3208.	2.0	22
793	Update Breast Cancer 2020 Part 2 â€” Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Und Frauenheilkunde, 2020, 80, 391-398.	0.8	12
794	BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. Breast Cancer Research and Treatment, 2020, 181, 323-329.	1.1	9
795	Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer. Cancer Treatment Reviews, 2020, 86, 102021.	3.4	89
796	Mainstream consent programs for genetic counseling in cancer patients: A systematic review. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 163-177.	0.7	29
797	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical Cancer Research, 2020, 26, 3881-3888.	3.2	59
798	Molecular subtypes and precision treatment of triple-negative breast cancer. Annals of Translational Medicine, 2020, 8, 499-499.	0.7	64
799	Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets. Frontiers in Cell and Developmental Biology, 2020, 8, 160.	1.8	46
800	BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. Cancers, 2020, 12, 828.	1.7	27
801	Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. Journal of Clinical Medicine, 2020, 9, 940.	1.0	79

#	ARTICLE	IF	CITATIONS
802	Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience. <i>Breast Care</i> , 2021, 16, 173-180.	0.8	3
803	Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 241-255.	0.7	10
804	Prognostic and predictive parameters in breast pathology: a pathologist's primer. <i>Modern Pathology</i> , 2021, 34, 94-106.	2.9	14
805	Family communication of genetic test results among women with inherited breast cancer genes. <i>Journal of Genetic Counseling</i> , 2021, 30, 701-709.	0.9	11
806	PARP inhibition in homologous-recombination-deficient early-stage breast cancer. <i>Annals of Oncology</i> , 2021, 32, 4-5.	0.6	1
807	Progress in systemic therapy for triple-negative breast cancer. <i>Frontiers of Medicine</i> , 2021, 15, 1-10.	1.5	16
808	Investigation into the origins of an ancient BRCA1 founder mutation identified among Chinese families in Singapore. <i>International Journal of Cancer</i> , 2021, 148, 637-645.	2.3	5
809	Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer. <i>Annals of Pharmacotherapy</i> , 2021, 55, 921-931.	0.9	38
810	Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. <i>Annals of Oncology</i> , 2021, 32, 58-65.	0.6	14
811	PARP Inhibitors in Cancer Diagnosis and Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1585-1594.	3.2	53
812	DNA Damage Repair Deficiency and Synthetic Lethality for Cancer Treatment. <i>Trends in Molecular Medicine</i> , 2021, 27, 91-92.	3.5	14
813	The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database. <i>Journal of Human Genetics</i> , 2021, 66, 307-314.	1.1	32
814	Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial. <i>Annals of Oncology</i> , 2021, 32, 218-228.	0.6	26
815	PARP inhibitors coming of age. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 69-70.	12.5	18
816	Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 358-372.	1.5	18
817	Updates on the treatment of invasive breast cancer: Quo Vadimus?. <i>Maturitas</i> , 2021, 145, 64-72.	1.0	7
818	Comprehensive molecular profiling broadens treatment options for breast cancer patients. <i>Cancer Medicine</i> , 2021, 10, 529-539.	1.3	23
819	Triple-negative breast cancer: promising prognostic biomarkers currently in development. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 135-148.	1.1	80

#	ARTICLE	IF	CITATIONS
820	Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling. <i>Molecular Cancer Research</i> , 2021, 19, 329-345.	1.5	13
821	Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. <i>Advances in Therapy</i> , 2021, 38, 109-136.	1.3	23
822	Training courses on hereditary breast and ovarian cancer to strengthen cross-sectoral care in underserved areas. <i>Patient Education and Counseling</i> , 2021, 104, 1431-1437.	1.0	2
823	Proteomic analysis of talazoparib resistance in triple-negative breast cancer cells. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22678.	1.4	6
824	Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. <i>Nature Cancer</i> , 2021, 2, 66-82.	5.7	126
825	Ascorbate kills breast cancer cells by rewiring metabolism via redox imbalance and energy crisis. <i>Free Radical Biology and Medicine</i> , 2021, 163, 196-209.	1.3	22
826	Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes. <i>Cancer Medicine</i> , 2021, 10, 933-943.	1.3	12
827	BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188459.	3.3	5
828	Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2021, 210, 112954.	2.6	41
829	A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. <i>Clinical Lung Cancer</i> , 2021, 22, e63-e66.	1.1	22
830	A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, 99-e217.	1.9	49
831	Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). <i>Annals of Oncology</i> , 2021, 32, 49-57.	0.6	92
832	Unique roles of rare variants in the genetics of complex diseases in humans. <i>Journal of Human Genetics</i> , 2021, 66, 11-23.	1.1	74
833	Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 436-440.	0.4	31
834	Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 73-84.	1.1	16
835	Drug repurposing for breast cancer therapy: Old weapon for new battle. <i>Seminars in Cancer Biology</i> , 2021, 68, 8-20.	4.3	74
836	Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients. <i>Journal of Cancer Education</i> , 2021, 36, 463-469.	0.6	18
837	Research advances and new challenges in overcoming triple-negative breast cancer. , 2021, 4, 517-542.		11

#	ARTICLE	IF	CITATIONS
838	Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110185.	1.4	9
839	Luminal A breast cancer resistance mechanisms and emerging treatments. , 2021, , 1-22.		2
840	Systemic Therapy for the Treatment of Breast Cancer. , 2021, , 81-87.		0
841	Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 109-117.	2.3	10
842	“Triple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinic” Cancer Journal (Sudbury, Mass), 2021, 27, 76-82.	1.0	4
844	Immunotherapy in Triple-Negative Breast Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 59-66.	1.0	36
845	Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110302.	1.4	6
846	BRCA testing and outcomes in women with breast cancer. Breast Cancer Research and Treatment, 2021, 186, 839-850.	1.1	5
847	Isochromanoidenolines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation. International Journal of Biological Sciences, 2021, 17, 986-994.	2.6	2
848	Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?. Breast Care, 2021, 16, 115-128.	0.8	10
849	DNA Damage Repair Inhibitor for Breast Cancer Treatment. Advances in Experimental Medicine and Biology, 2021, 1187, 159-179.	0.8	0
850	The Potential Predictors in Chemotherapy Sensitivity. Advances in Experimental Medicine and Biology, 2021, 1187, 381-389.	0.8	0
851	Case-only Approach in Randomized Clinical Trials -Evaluation of Power to Detect a Treatment Effect Predictive Marker-. Japanese Journal of Biometrics, 2021, 41, 137-149.	0.0	0
852	PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations. Cancer Journal (Sudbury, Mass), 2021, 27, 67-75.	1.0	7
853	Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 571-584.	0.7	26
854	Computational Prediction of Chemical Tools for Identification and Validation of Synthetic Lethal Interaction Networks. Methods in Molecular Biology, 2021, 2381, 333-358.	0.4	0
855	The evolution and advances of biomarker use in clinical trials for breast cancer treatment—a narrative review. Translational Breast Cancer Research, 0, 2, 6-6.	0.4	0
856	p66ShcA potentiates the cytotoxic response of triple negative breast cancers to PARP inhibitors. JCI Insight, 2021, 6, .	2.3	0

#	ARTICLE	IF	CITATIONS
857	Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic <i>BRCA2</i> mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110069.	1.4	5
858	The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2111-2119.	0.7	45
859	A novel somatic <i>BRCA2</i> point mutation in a metastatic pancreatic cancer patient: a case report. <i>BMC Medical Genomics</i> , 2021, 14, 6.	0.7	4
860	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab007.	1.4	11
861	The advance of adjuvant treatment for triple-negative breast cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	11
862	Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4101-4109.	1.9	436
863	Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. <i>International Journal of Medical Sciences</i> , 2021, 18, 2245-2250.	1.1	5
864	The <i>RAD51D</i> c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 869-877.	1.1	2
865	Clinical application of liquid biopsies to detect somatic <i>BRCA1/2</i> mutations and guide potential therapeutic intervention for patients with metastatic breast cancer. <i>Oncotarget</i> , 2021, 12, 63-65.	0.8	1
866	Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer. <i>Breast Care</i> , 2021, 16, 101-107.	0.8	2
867	Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 648-654.	2.8	11
868	Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. <i>Investigational New Drugs</i> , 2021, 39, 796-802.	1.2	2
869	<i>BRCA1</i> Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis. <i>Journal of Breast Cancer</i> , 2021, 24, 474.	0.8	5
870	Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 636.	1.8	29
871	Hereditary Cancer Counseling and Germline Genetic Testing. , 2021, , 305-317.		0
872	Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. <i>Advanced Biology</i> , 2021, 5, 1900236.	1.4	13
873	A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. <i>Scientific Reports</i> , 2021, 11, 4433.	1.6	10
874	Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. <i>Lancet Haematology</i> , 2021, 8, e122-e134.	2.2	139

#	ARTICLE	IF	CITATIONS
875	From Race-Based to Precision Oncology: Leveraging Behavioral Economics and the Electronic Health Record to Advance Health Equity in Cancer Care. <i>JCO Precision Oncology</i> , 2021, 5, 403-407.	1.5	3
876	Treatment-emergent neuroendocrine prostate cancer with a germline <i>BRCA2</i> mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a005801.	0.5	9
877	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. <i>Genes</i> , 2021, 12, 285.	1.0	18
878	Atezolizumab and <i>nab</i> -Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1005-1016.	3.0	171
879	Awareness and Availability of Routine Germline <i>BRCA1/2</i> Mutation Testing in Patients with Advanced Breast Cancer in Germany. <i>Breast Care</i> , 2022, 17, 40-46.	0.8	3
880	Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea. <i>Diagnostics</i> , 2021, 11, 370.	1.3	2
881	Oncologist-led <i>BRCA</i> counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes. <i>Journal of Medical Genetics</i> , 2022, 59, 220-229.	1.5	9
882	Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability. <i>Cells</i> , 2021, 10, 337.	1.8	5
883	Association Between Single-Nucleotide Polymorphisms in Breast Cancer Susceptibility Genes and Clinicopathological Characteristics. <i>Clinical Epidemiology</i> , 2021, Volume 13, 103-112.	1.5	4
884	Amongst Women Stratified to Receive Endocrine Therapy on the Basis of Their Tumor Estrogen and Progesterone Receptor Levels, Those with Higher Tumor Progesterone Receptor Levels Had a Better Outcome Than Those with Lower Levels of Tumor Progesterone Receptor. <i>Cancers</i> , 2021, 13, 905.	1.7	4
885	Clinical Candidates Targeting the <i>ATR</i> - <i>CHK1</i> - <i>WEE1</i> Axis in Cancer. <i>Cancers</i> , 2021, 13, 795.	1.7	50
886	Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy. <i>Journal of International Medical Research</i> , 2021, 49, 030006052199101.	0.4	5
887	Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses. <i>BMC Cancer</i> , 2021, 21, 199.	1.1	12
888	Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials. <i>Journal of Chemotherapy</i> , 2021, 33, 452-461.	0.7	5
889	Patient-Specific Network for Personalized Breast Cancer Therapy with Multi-Omics Data. <i>Entropy</i> , 2021, 23, 225.	1.1	5
890	DNA Repair Pathways in Cancer Therapy and Resistance. <i>Frontiers in Pharmacology</i> , 2020, 11, 629266.	1.6	172
892	Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies. <i>Cancers</i> , 2021, 13, 612.	1.7	6
893	A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. <i>International Journal of Cancer</i> , 2021, 148, 3041-3050.	2.3	5

#	ARTICLE	IF	CITATIONS
894	Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 19.	0.6	1
895	Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). <i>Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)</i> . <i>ESMO Open</i> , 2021, 6, 100019.	2.0	12
896	Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 894.	1.7	6
897	Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer. <i>Journal of Human Genetics</i> , 2021, 66, 785-793.	1.1	2
898	Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining. <i>Cancer Research</i> , 2021, 81, 3333-3346.	0.4	16
899	Clinical application of circulating tumor DNA in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1431-1442.	1.2	5
901	WNT inhibition creates a BRCA-like state in Wnt-addicted cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e13349.	3.3	28
902	Response to Vemurafenib in Metastatic Triple-Negative Breast Cancer Harboring a BRAF V600E Mutation: A Case Report and Electronically Captured Patient-Reported Outcome. <i>Case Reports in Oncology</i> , 2021, 14, 616-621.	0.3	13
903	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 473-487.	12.5	139
904	Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence. <i>Cancers</i> , 2021, 13, 1586.	1.7	9
905	Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 1080.	1.7	10
906	Overview of recent advances in metastatic triple negative breast cancer. <i>World Journal of Clinical Oncology</i> , 2021, 12, 164-182.	0.9	42
907	Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer. <i>Oncology Letters</i> , 2021, 21, 365.	0.8	5
908	Targeting "undruggable" c-Myc protein by synthetic lethality. <i>Frontiers of Medicine</i> , 2021, 15, 541-550.	1.5	8
909	Cisplatin +/and rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 29.	2.3	15
910	Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2382-2418.	2.9	61
911	A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. <i>Oral Oncology</i> , 2021, 114, 105171.	0.8	13
912	Pancreatic Acinar Cell Carcinoma with Germline BRCA2 Mutation and Severe Pancreatic Panniculitis: A Case Report. <i>Visceral Medicine</i> , 2021, 37, 447-450.	0.5	3

#	ARTICLE	IF	CITATIONS
913	Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3201-3214.	3.2	27
914	Targeting the Hypoxic and Acidic Tumor Microenvironment with pH-Sensitive Peptides. <i>Cells</i> , 2021, 10, 541.	1.8	33
915	Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 451-461.	1.9	6
916	Germline Mutations in Other Homologous Recombination Repair-Related Genes Than <i>BRCA1/2</i> : Predictive or Prognostic Factors?. <i>Journal of Personalized Medicine</i> , 2021, 11, 245.	1.1	14
917	Metaplastic breast cancer: an old histotype but a current therapeutic problem. <i>Future Oncology</i> , 2021, 17, 955-963.	1.1	3
918	Systematic characterization of mutations altering protein degradation in human cancers. <i>Molecular Cell</i> , 2021, 81, 1292-1308.e11.	4.5	36
919	PARP inhibitors in breast and ovarian cancer with <i>BRCA</i> mutations: a meta-analysis of survival. <i>Aging</i> , 2021, 13, 8975-8988.	1.4	13
920	Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre. <i>European Journal of Human Genetics</i> , 2021, 29, 872-880.	1.4	27
921	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> mutations in Japanese patients with triple-negative breast cancer: A single institute retrospective study. <i>Molecular and Clinical Oncology</i> , 2021, 14, 96.	0.4	3
922	The overexpression of DNA repair genes in invasive ductal and lobular breast carcinomas: Insights on individual variations and precision medicine. <i>PLoS ONE</i> , 2021, 16, e0247837.	1.1	6
923	Reacción liquenoide inducida por niraparib. <i>Piel</i> , 2021, 36, 204-206.	0.0	0
924	The PARP Way to Epigenetic Changes. <i>Genes</i> , 2021, 12, 446.	1.0	24
925	Clinical practice guidelines for <i>BRCA1</i> and <i>BRCA2</i> genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	1.3	81
926	Current Status and Future Targeted Therapy in Adrenocortical Cancer. <i>Frontiers in Endocrinology</i> , 2021, 12, 613248.	1.5	22
927	Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline <i>BRCA1/2</i> Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. <i>Cancer Research and Treatment</i> , 2021, 53, 1084-1095.	1.3	5
928	An Overview of PARP Inhibitors for the Treatment of Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 255-282.	1.7	182
929	Hereditary breast cancer and ovarian cancer: clinical course and treatment. <i>Opuholi Zenskoj Reproktivnoy Sistemy</i> , 2021, 16, 54-65.	0.1	0
930	Emerging Therapeutics for Patients with Triple-Negative Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 57.	1.8	30

#	ARTICLE	IF	CITATIONS
931	Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays. <i>British Journal of Cancer</i> , 2021, 125, 7-14.	2.9	14
932	Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 608369.	1.6	8
933	Breast Cancer Brain Metastasis – Overview of Disease State, Treatment Options and Future Perspectives. <i>Cancers</i> , 2021, 13, 1078.	1.7	41
934	Prostate cancer and PARP inhibitors: progress and challenges. <i>Journal of Hematology and Oncology</i> , 2021, 14, 51.	6.9	68
935	Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting. <i>Diagnostics</i> , 2021, 11, 733.	1.3	13
936	Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3916.	1.8	13
937	Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2815-2819.	1.0	2
939	Nanomaterial Complexes Enriched With Natural Compounds Used in Cancer Therapies: A Perspective for Clinical Application. <i>Frontiers in Oncology</i> , 2021, 11, 664380.	1.3	8
940	Baseline knowledge and receptiveness to genetic testing for hereditary breast and ovarian cancer syndromes in Chinese high-risk females. <i>Journal of Community Genetics</i> , 2021, 12, 431-438.	0.5	3
941	Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells. <i>BMC Cancer</i> , 2021, 21, 448.	1.1	8
942	In the literature: February 2021. <i>ESMO Open</i> , 2021, 6, 100061.	2.0	0
943	Novel Ring Systems: Spiro[Cycloalkane] Derivatives of Triazolo- and Tetrazolo-Pyridazines. <i>Molecules</i> , 2021, 26, 2140.	1.7	3
946	Personalized and targeted therapies. <i>ChemistrySelect</i> , 2023, 8, 2103-2126.	0.7	0
947	CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 676-686.	1.5	20
948	Routine Molecular Pathology Diagnostics in Precision Oncology. <i>Deutsches Arzteblatt International</i> , 2021, 118, .	0.6	2
949	Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 122.	3.5	35
950	DNA damage response inhibitors: An avenue for TNBC treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188521.	3.3	26
951	PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer. <i>Medical Oncology</i> , 2021, 38, 61.	1.2	2

#	ARTICLE	IF	CITATIONS
952	In vivo visualization of PARP inhibitor pharmacodynamics. JCI Insight, 2021, 6, .	2.3	14
953	Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, .	0.6	2
954	Zebrafish Avatar to Develop Precision Breast Cancer Therapies.. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, .	0.9	3
955	Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil. Surgical and Experimental Pathology, 2021, 4, .	0.2	2
956	Cyclin-dependent kinase 4 and 6 inhibitors at the crossroads: the combinational therapeutic strategies in breast cancer—a narrative review. Translational Breast Cancer Research, 2021, 2, 13-13.	0.4	0
957	Prognostic factors for patients with metastatic breast cancer: a literature review. Translational Cancer Research, 2021, 10, 1644-1655.	0.4	0
958	PARP1-Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation. Cancers, 2021, 13, 2092.	1.7	4
959	Genomic Correlates of DNA Damage in Breast Cancer Subtypes. Cancers, 2021, 13, 2117.	1.7	3
960	Implementing clinical practice guidelines for breast cancer management: searching for homogeneity in real-life heterogeneity. Translational Breast Cancer Research, 2021, 2, 9-9.	0.4	0
961	Basic and Preclinical Research for Personalized Medicine. Journal of Personalized Medicine, 2021, 11, 354.	1.1	8
962	Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer. Journal of Personalized Medicine, 2021, 11, 340.	1.1	7
963	PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. The Cochrane Library, 2021, 2021, CD011395.	1.5	19
964	Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. Clinical Gastroenterology and Hepatology, 2022, 20, e508-e528.	2.4	36
965	Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers, 2021, 13, 1656.	1.7	16
966	Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials. Expert Opinion on Emerging Drugs, 2021, 26, 131-147.	1.0	5
967	Synthetic Lethality in Cancer Therapeutics: The Next Generation. Cancer Discovery, 2021, 11, 1626-1635.	7.7	91
969	Ovarian metastasis from breast cancer mimicking a primary ovarian neoplasm: A case report. Molecular and Clinical Oncology, 2021, 15, 135.	0.4	4
970	Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity. Scientific Reports, 2021, 11, 10571.	1.6	0

#	ARTICLE	IF	CITATIONS
971	Precision medicine for the treatment of triple negative breast cancer: opportunities and challenges. Expert Review of Precision Medicine and Drug Development, 2021, 6, 259-270.	0.4	1
972	Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. <i>Nutrients</i> , 2021, 13, 1718.	1.7	10
973	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.	5.8	116
974	Four novel BRCA variants found in Chinese hereditary breast cancer patients by next-generation sequencing. <i>Clinica Chimica Acta</i> , 2021, 516, 55-63.	0.5	3
976	Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas. <i>Laboratory Investigation</i> , 2021, 101, 1048-1059.	1.7	6
977	Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 648139.	1.3	18
978	Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. <i>Journal of Clinical Oncology</i> , 2021, 39, 1631-1640.	0.8	62
979	Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. <i>Current Oncology</i> , 2021, 28, 1803-1822.	0.9	24
980	Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive. <i>Pharmaceuticals</i> , 2021, 14, 455.	1.7	18
981	Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2262.	1.7	9
982	Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: Age as a significant treatment effect-modifier. <i>Journal of the Formosan Medical Association</i> , 2021, , .	0.8	2
983	Molecular Determinants of Gastrointestinal Cancers. <i>Advances in Oncology</i> , 2021, 1, 311-325.	0.1	0
984	Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer – Association With Patient and Disease Characteristics and Effect on Prognosis. <i>Journal of Clinical Oncology</i> , 2021, 39, 1619-1630.	0.8	39
985	Breast cancer. <i>Lancet, The</i> , 2021, 397, 1750-1769.	6.3	731
986	Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor. <i>Cancer Letters</i> , 2021, 506, 23-34.	3.2	12
987	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (â€œMETRICâ€): a randomized multicenter study. <i>Npj Breast Cancer</i> , 2021, 7, 57.	2.3	26
988	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 48.	2.3	3
990	Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	5

#	ARTICLE	IF	CITATIONS
991	Study of the Genetic Variants in BRCA1/2 and Non-BRCA Genes in a Population-Based Cohort of 2155 Breast/Ovary Cancer Patients, Including 443 Triple-Negative Breast Cancer Patients, in Argentina. <i>Cancers</i> , 2021, 13, 2711.	1.7	7
992	Metastatic Triple Negative Breast Cancer: The New Era of Thinking. <i>Forum of Clinical Oncology</i> , 2021, .	0.1	0
993	Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. <i>Cancers</i> , 2021, 13, 2249.	1.7	28
994	Pathology of breast cancer metastasis and a view of metastasis to the brain. <i>International Journal of Neuroscience</i> , 2023, 133, 544-554.	0.8	1
995	BRCA mutated pancreatic cancer: A change is coming. <i>World Journal of Gastroenterology</i> , 2021, 27, 1943-1958.	1.4	42
996	Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2929-2939.	1.0	3
997	Update Breast Cancer 2021 Part 1 – Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 526-538.	0.8	10
998	Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment. <i>Cancers</i> , 2021, 13, 2559.	1.7	21
999	The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials. <i>Biomolecules</i> , 2021, 11, 722.	1.8	9
1000	Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2021, 13, 216-226.	0.5	5
1001	Targeted Therapies in Older Adults With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2128-2137.	0.8	7
1002	Precision Oncology. <i>Advances in Oncology</i> , 2021, 1, 97-112.	0.1	0
1003	Curing pancreatic cancer. <i>Seminars in Cancer Biology</i> , 2021, 76, 232-246.	4.3	22
1004	Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. <i>Clinical Lung Cancer</i> , 2021, 22, 187-194.e1.	1.1	18
1005	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152.	1.3	41
1006	KIF23 promotes triple negative breast cancer through activating epithelial-mesenchymal transition. <i>Gland Surgery</i> , 2021, 10, 1941-1950.	0.5	19
1007	Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-23.	0.9	3
1008	Clinical Trials and Breast Cancer Disparities. <i>Current Breast Cancer Reports</i> , 2021, 13, 186-196.	0.5	3

#	ARTICLE	IF	CITATIONS
1009	Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2394-2405.	13.9	764
1010	Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. <i>Gynecologic Oncology</i> , 2021, 161, 653-659.	0.6	26
1011	PARP inhibitor treatment of advanced breast cancer beyond the <i>BRCA</i> -mutated type: a meta-analysis. <i>Future Oncology</i> , 2021, 17, 2381-2393.	1.1	7
1012	Targeted Sequencing of Taiwanese Breast Cancer with Risk Stratification by the Concurrent Genes Signature: A Feasibility Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 613.	1.1	2
1013	An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers. <i>Cancers</i> , 2021, 13, 3113.	1.7	0
1014	A Case-Based Approach to Understanding Complex Genetic Information in an Evolving Landscape. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e328-e338.	1.8	2
1015	Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. <i>Frontiers in Oncology</i> , 2021, 11, 686776.	1.3	13
1016	Adjuvant Olaparib Improves Disease-Free Survival in Early, High-Risk, <i>BRCA</i> -Mutated, <i>HER2</i> - Breast Cancer. <i>Oncologist</i> , 2021, 26, S3-S4.	1.9	2
1017	A narrative review of chemotherapy in advanced triple negative breast cancer. <i>Precision Cancer Medicine</i> , 0, 4, 13-13.	1.8	2
1018	Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 537-547.	2.7	58
1019	Oligometastatic Breast Cancer: How to Manage It?. <i>Journal of Personalized Medicine</i> , 2021, 11, 532.	1.1	8
1020	Trials of Immunotherapy in Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2021, 13, 171-185.	0.5	1
1021	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 518.	1.1	8
1022	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. <i>Oncologist</i> , 2021, 26, 835-844.	1.9	16
1023	Double heterozygotes of <i>BRCA1/BRCA2</i> and mismatch repair gene pathogenic variants: case series and clinical implications. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 685-694.	1.1	4
1024	Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic <i>BRCA2</i> Mutation. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3895-3901.	1.0	9
1025	Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 605-611.	1.1	4
1026	Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. <i>Breast</i> , 2021, 57, 86-94.	0.9	6

#	ARTICLE	IF	CITATIONS
1027	Cancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis. <i>Cancers</i> , 2021, 13, 3146.	1.7	29
1028	Evaluating the impacts of emerging cancer therapies on ovarian function. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 18, 15-28.	0.6	6
1029	Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 654-665.	0.8	4
1030	Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 682872.	1.3	13
1031	Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer. <i>PLoS ONE</i> , 2021, 16, e0252822.	1.1	10
1032	NGS in Lung, Breast, and Unknown Primary Cancer in Colombia: A Multidisciplinary Consensus on Challenges and Opportunities. <i>JCO Global Oncology</i> , 2021, 7, 1012-1023.	0.8	7
1033	Triple negative breast cancer: emerging light on the horizon – a narrative review. <i>Precision Cancer Medicine</i> , 0, 4, 12-12.	1.8	1
1034	VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 683038.	1.8	9
1035	Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 748-758.	2.9	15
1036	Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 681476.	1.3	71
1037	Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2978.	1.7	12
1038	BBIT20 inhibits homologous DNA repair with disruption of the BRCA1 – BARD1 interaction in breast and ovarian cancer. <i>British Journal of Pharmacology</i> , 2021, 178, 3627-3647.	2.7	13
1039	Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover). <i>Clinical Cancer Research</i> , 2021, 27, 4983-4993.	3.2	9
1040	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. <i>Oncologist</i> , 2021, 26, 827-834.	1.9	28
1041	A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, 1-9.	1.1	6
1042	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
1043	Role of molecular signature to differentiate second primary lung cancer from metastasis in a patient with squamous cell carcinoma of oral cavity. <i>Cancer Reports</i> , 2021, 4, e1363.	0.6	2
1044	Neutrophils Alter DNA Repair Landscape to Impact Survival and Shape Distinct Therapeutic Phenotypes of Colorectal Cancer. <i>Gastroenterology</i> , 2021, 161, 225-238.e15.	0.6	17

#	ARTICLE	IF	CITATIONS
1045	Olaparib for the treatment of metastatic prostate cancer. <i>Future Oncology</i> , 2021, 17, 2413-2429.	1.1	2
1046	Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. <i>Nature Cancer</i> , 2021, 2, 680-692.	5.7	56
1047	Impact of Tumor Assessment Frequency on Statistical Power in Randomized Cancer Clinical Trials Evaluating Progression-Free Survival. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1258-1264.	0.8	1
1048	Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells. <i>Frontiers in Oncology</i> , 2021, 11, 694793.	1.3	12
1049	Expert review on systemic treatment in the St. Gallen International Breast Cancer Conference 2021. <i>Translational Breast Cancer Research</i> , 0, 2, 17-17.	0.4	2
1050	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114753.	2.8	15
1051	Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer. <i>Molecular Oncology</i> , 2022, 16, 2413-2431.	2.1	3
1052	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	0.8	40
1053	BRCA mutations and gastrointestinal cancers: When to expect the unexpected?. <i>World Journal of Clinical Oncology</i> , 2021, 12, 565-580.	0.9	10
1054	Highly multiplexed rapid DNA detection with single-nucleotide specificity via convective PCR in a portable device. <i>Nature Biomedical Engineering</i> , 2021, 5, 702-712.	11.6	41
1055	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 773-791.	12.5	198
1056	Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1825-1837.	0.9	11
1057	ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. <i>Cells</i> , 2021, 10, 1659.	1.8	16
1058	Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology. <i>Seminars in Cancer Biology</i> , 2022, 84, 23-31.	4.3	10
1059	The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 871-878.	2.3	10
1060	Functional genomics for breast cancer drug target discovery. <i>Journal of Human Genetics</i> , 2021, 66, 927-935.	1.1	9
1061	Enhanced Paclitaxel Efficacy to Suppress Triple-Negative Breast Cancer Progression Using Metronomic Chemotherapy with a Controlled Release System of Electrospun Poly-d,l-Lactide-Co-Glycolide (PLGA) Nanofibers. <i>Cancers</i> , 2021, 13, 3350.	1.7	16
1062	A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status. <i>Oncology and Therapy</i> , 2021, 9, 575-589.	1.0	26

#	ARTICLE	IF	CITATIONS
1063	Landmark trials in the medical oncology management of metastatic breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 246-258.	0.8	4
1064	Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7154.	1.8	5
1065	Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance. <i>Journal of the National Cancer Center</i> , 2021, 1, 75-87.	3.0	20
1066	Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. <i>Clinical Cancer Research</i> , 2021, 27, 5482-5491.	3.2	25
1068	Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7884.	1.8	8
1069	Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 1-13.	1.1	3
1070	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. <i>European Journal of Cancer</i> , 2021, 152, 68-77.	1.3	18
1071	Precision medicine in breast cancer: From clinical trials to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 98, 102223.	3.4	34
1072	Combination of Olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP Phase I trial. <i>International Journal of Cancer</i> , 2021, 149, 1828-1832.	2.3	20
1073	Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3959-3977.	0.8	121
1074	Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 5223-5237.	0.9	30
1075	Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs. <i>Cancers</i> , 2021, 13, 3697.	1.7	41
1076	Genetic Landscape of Male Breast Cancer. <i>Cancers</i> , 2021, 13, 3535.	1.7	22
1077	Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics. <i>JCO Precision Oncology</i> , 2021, 5, 1297-1311.	1.5	9
1078	Following NCCN guidelines within one hospital system in the United States: Comparison between cancer centers and genetic counselor utilization. <i>Journal of Genetic Counseling</i> , 2021, , .	0.9	0
1079	Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 245-253.	3.0	5
1080	The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data. <i>Clinical Breast Cancer</i> , 2022, 22, 10-25.	1.1	7
1081	Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention. <i>JCO Precision Oncology</i> , 2021, 5, 1387-1396.	1.5	23

#	ARTICLE	IF	CITATIONS
1082	Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3199-3206.	0.8	5
1083	Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 760-774.	0.9	1
1084	Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than <i>BRCA1</i> or <i>BRCA2</i> . <i>Journal of Clinical Oncology</i> , 2021, 39, 2528-2534.	0.8	11
1085	Novel RAF/MEK inhibitor CH5126766/VS6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer. <i>Cancer Science</i> , 2021, 112, 4166-4175.	1.7	6
1086	Response to olaparib in metastatic lung adenocarcinoma with germline <i>BRCA2</i> mutation. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	6
1087	Targeting the DNA damage response in immuno-oncology: developments and opportunities. <i>Nature Reviews Cancer</i> , 2021, 21, 701-717.	12.8	150
1088	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
1089	Breast Cancer Treatments: Updates and New Challenges. <i>Journal of Personalized Medicine</i> , 2021, 11, 808.	1.1	108
1090	Cytotoxic and targeted therapy for <i>BRCA1/2</i> -driven cancers. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 36.	0.6	11
1091	Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). <i>JCO Precision Oncology</i> , 2021, 5, 1432-1442.	1.5	29
1092	Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without <i>BRCA1/2</i> mutations. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 641-651.	1.1	16
1093	First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. <i>Annals of Oncology</i> , 2021, 32, 983-993.	0.6	205
1094	Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 541-553.	1.3	4
1095	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i> , <i>BRCA2</i> , or <i>PALB2</i> . <i>Journal of Clinical Oncology</i> , 2021, 39, 2497-2505.	0.8	113
1096	Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials. <i>Annals of Translational Medicine</i> , 2021, 9, 1229-1229.	0.7	10
1097	Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC). <i>International Journal of Molecular Sciences</i> , 2021, 22, 8924.	1.8	1
1098	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	0.8	83
1099	Experience in treating <i>BRCA</i> -associated breast cancer. The <i>BRCA</i> -history of a family. <i>Meditinskiy Sovet</i> , 2021, , 34-41.	0.1	1

#	ARTICLE	IF	CITATIONS
1100	Comparison of clinical pharmacogenetic recommendations across therapeutic areas. <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, .	0.7	2
1101	Breast Cancer in Jamaica: Stage, Grade and Molecular Subtype Distributions Across Age Blocks, the Implications for Screening and Treatment. <i>World Journal of Oncology</i> , 2021, 12, 93-103.	0.6	10
1102	Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study. <i>Pharmaceuticals</i> , 2021, 14, 804.	1.7	13
1103	Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in <i>BRCA1</i> , <i>BRCA2</i> or <i>ATM</i> ? <i>Pharmacogenomics</i> , 2021, 22, 809-819.	0.6	6
1104	Open questions and controversies in the systemic treatment of breast cancer. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 591-596.	1.1	1
1105	Black Disparities in Targeted Therapy Clinical Trials – A Call for Future Reset. <i>Journal of Education and Teaching in Emergency Medicine</i> , 2021, 7, 8-28.	0.0	1
1106	Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 4059.	1.7	8
1107	Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer. <i>Cancers</i> , 2021, 13, 4132.	1.7	4
1108	Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2028-2036.e2.	0.3	17
1109	Ovarian-Cancer-Associated Extracellular Vesicles: Microenvironmental Regulation and Potential Clinical Applications. <i>Cells</i> , 2021, 10, 2272.	1.8	17
1110	<i>In-vitro</i> Evaluation of Isatin Derivatives as Potent Anti-Breast Cancer Agents against MCF-7, MDA MB 231, MDA-MB 435 and MDA-MB 468 Breast Cancers Cell Lines: A Review. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1883-1896.	0.9	7
1111	Lysine Methyltransferase Inhibitors Impair H4K20me2 and 53BP1 Foci in Response to DNA Damage in Sarcomas, a Synthetic Lethality Strategy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 715126.	1.8	5
1112	Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test. <i>Journal of Clinical Oncology</i> , 2021, 39, 3415-3418.	0.8	9
1113	Genomic Determinants of Homologous Recombination Deficiency across Human Cancers. <i>Cancers</i> , 2021, 13, 4572.	1.7	3
1114	Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1021-1030.	0.6	4
1115	Challenges of Treating Young Women With Cancer in the Era of New Oncologic Treatments. <i>Revista De Investigacion Clinica</i> , 2021, 73, 302-305.	0.2	0
1116	Genetic testing in patients with triple-negative or hereditary breast cancer. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 584-590.	1.1	1
1117	Successful treatment of refractory lung adenocarcinoma harboring a germline <i>BRCA2</i> mutation with olaparib: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 7498-7503.	0.3	8

#	ARTICLE	IF	CITATIONS
1118	Landscape Analysis of Breast Cancer and Acute Myeloid Leukemia Trials Using the My Cancer Genome Clinical Trial Data Model. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 975-984.	1.0	1
1119	Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. <i>Expert Opinion on Drug Safety</i> , 2021, , 1-13.	1.0	0
1120	Overexpression of BIRC6 driven by EGF-JNK-HECTD1 signaling is a potential therapeutic target for triple-negative breast cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 798-812.	2.3	12
1121	Ovarian Cancerâ€™Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6559-6569.	3.2	9
1122	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. <i>Clinical Cancer Research</i> , 2021, 27, 6106-6114.	3.2	9
1123	Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 114.	2.3	3
1124	Discovery of Potent and Selective CDK9 Degradors for Targeting Transcription Regulation in Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14822-14847.	2.9	19
1125	Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. <i>Clinical Lung Cancer</i> , 2021, 22, e703-e707.	1.1	5
1126	Repositioning PARP inhibitors in the treatment of thoracic malignancies. <i>Cancer Treatment Reviews</i> , 2021, 99, 102256.	3.4	7
1127	The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 531-548.	1.9	16
1128	Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100231.	0.6	16
1129	Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer. <i>Healthcare (Switzerland)</i> , 2021, 9, 1203.	1.0	3
1130	B4GALNT2 Gene Promotes Proliferation, and Invasiveness and Migration Abilities of Model Triple Negative Breast Cancer (TNBC) Cells by Interacting With HLA-B Protein. <i>Frontiers in Oncology</i> , 2021, 11, 722828.	1.3	5
1131	Management of hormone receptorâ€™positive, human epidermal growth factor 2â€™negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 189-201.	1.1	10
1132	A Step Forward in Realizing the Promise of Genomic Medicine for Childhood Rhabdomyosarcoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2851-2854.	0.8	0
1133	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. <i>Cancer Treatment Reviews</i> , 2021, 99, 102255.	3.4	25
1134	Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 703802.	1.3	10
1135	Efficacy and safety of first-line veliparib and carboplatinâ€™paclitaxel in patients with HER2â€™ advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. <i>European Journal of Cancer</i> , 2021, 154, 35-45.	1.3	10

#	ARTICLE	IF	CITATIONS
1136	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 271-279.	3.0	27
1137	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 701-741.	1.7	7
1138	Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD. <i>Annals of Oncology</i> , 2021, 32, 1582-1589.	0.6	16
1139	Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies. <i>Clinical Breast Cancer</i> , 2021, 21, 509-520.	1.1	13
1140	A review of immune checkpoint blockade in breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 208-225.	0.8	11
1141	Bisppecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer. , 2021, 9, e003468.		17
1142	Bioactive nanotherapeutic trends to combat triple negative breast cancer. <i>Bioactive Materials</i> , 2021, 6, 3269-3287.	8.6	31
1143	Diagnostic Classification and Genomic Analyses of Cancer. <i>Laboratory Medicine Online</i> , 2021, 11, 223-229.	0.0	0
1144	Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2021, 59, 44-50.	0.9	3
1145	Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. <i>Trends in Cancer</i> , 2021, 7, 958-970.	3.8	18
1146	Breast Cancer in Women Over 65 years- a Review of Screening and Treatment Options. <i>Clinics in Geriatric Medicine</i> , 2021, 37, 611-623.	1.0	8
1147	Progress and challenges of immunotherapy in triple-negative breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188593.	3.3	106
1148	Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100097.	0.1	1
1149	Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review. <i>Breast</i> , 2021, 60, 26-34.	0.9	9
1150	Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 63-80.	2.3	34
1151	The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002.		0
1152	Triple Negative Breast Cancer. , 2022, , 35-48.		1
1154	From <i>BRCA1</i> to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes. <i>Breast Care</i> , 2021, 16, 202-213.	0.8	7

#	ARTICLE	IF	CITATIONS
1155	Mutant SF3B1 promotes AKT- and NF- κ B-driven mammary tumorigenesis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	22
1156	The role of PARP inhibitors in <i>BRCA</i> mutated pancreatic cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110148.	1.4	21
1157	Somatic data usage for classification of germ line variants. , 2021, , 169-192.		0
1158	Integrating PARP inhibitors into the management of breast cancer: where are we?. <i>Chinese Clinical Oncology</i> , 2021, 10, 50-50.	0.4	4
1159	Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model. <i>International Journal of Biological Sciences</i> , 2021, 17, 689-701.	2.6	2
1160	Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342110024.	0.6	16
1161	Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population. <i>Annals of Medicine</i> , 2021, 53, 1358-1369.	1.5	8
1162	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342199585.	0.6	22
1163	The cancer-testis gene, <i>MEIOB</i> , sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency. <i>Cancer Biology and Medicine</i> , 2021, 18, 74-87.	1.4	7
1164	Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients. <i>Cancer Medicine</i> , 2020, 9, 2427-2434.	1.3	7
1165	Review ctDNA and Breast Cancer. <i>Recent Results in Cancer Research</i> , 2020, 215, 231-252.	1.8	16
1166	Role of Next-Generation Sequencing Technologies in Personalized Medicine. , 2020, , 125-154.		13
1167	Triple-Negative Breast Cancer. , 2020, , 209-223.		1
1168	Maligne Tumoren der Mamma. , 2019, , 1-31.		1
1169	Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 421-428.	1.1	23
1171	Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 383-390.	1.1	18
1172	PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102973.	2.0	31
1173	Functional profiling of nucleotide Excision repair in breast cancer. <i>DNA Repair</i> , 2019, 82, 102697.	1.3	10

#	ARTICLE	IF	CITATIONS
1174	Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice. <i>Oncogene</i> , 2020, 39, 2835-2843.	2.6	15
1175	Challenges and future of precision medicine strategies for breast cancer based on a database on drug reactions. <i>Bioscience Reports</i> , 2019, 39, .	1.1	12
1176	Homologous recombination repair deficiency as a therapeutic target in sarcoma. <i>Seminars in Oncology</i> , 2020, 47, 380-389.	0.8	26
1177	Atezolizumab for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 151-158.	1.1	60
1178	Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review. <i>Journal of Pancreatic Cancer</i> , 2020, 6, 107-115.	1.6	5
1179	Expression Patterns and Prognostic Value of DNA Damage Repair Proteins in Resected Pancreatic Neuroendocrine Neoplasms. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	2.1	9
1181	Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?. <i>British Journal of Pharmacology</i> , 2020, 177, 3635-3645.	2.7	52
1182	Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 89-93.	1.2	30
1183	The evolving landscape of predictive biomarkers of response to PARP inhibitors. <i>Journal of Clinical Investigation</i> , 2018, 128, 1727-1730.	3.9	47
1184	DNA repair defects and implications for immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 4236-4242.	3.9	59
1185	PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 1211-1228.	3.9	222
1186	Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor-Positive Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822342097638.	0.6	3
1187	Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer. <i>F1000Research</i> , 2019, 8, 591.	0.8	15
1188	Triple-negative breast cancer: recent treatment advances. <i>F1000Research</i> , 2019, 8, 1342.	0.8	152
1189	Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance. <i>Yeungnam University Journal of Medicine</i> , 2020, 37, 230-235.	0.7	9
1190	Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures. <i>PLoS ONE</i> , 2020, 15, e0239197.	1.1	13
1191	A review of current progress in triple-negative breast cancer therapy. <i>Open Medicine (Poland)</i> , 2020, 15, 1143-1149.	0.6	46
1192	<i>BRCA</i> Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18-64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas - United States, 2009-2014. <i>MMWR Surveillance Summaries</i> , 2017, 66, 1-11.	18.6	33

#	ARTICLE	IF	CITATIONS
1193	Level of tumor-infiltrating lymphocytes and PD status as potential prognostic markers of survival and therapy effectiveness in triple-negative breast cancer. <i>Opuholi Zenskoj Reproktivnoj Sistemy</i> , 2020, 16, 65-70.	0.1	5
1194	Spectrum and frequency of BRCA1, BRCA2, CHEK2, PALB2, RAD50 mutations in breast cancer patients in the Republic of Bashkortostan. <i>Kazan Medical Journal</i> , 2020, 101, 691-697.	0.1	3
1195	Caspase-3 knockout attenuates radiation-induced tumor repopulation via impairing the ATM/p53/Cox-2/PGE2 pathway in non-small cell lung cancer. <i>Aging</i> , 2020, 12, 21758-21776.	1.4	16
1196	Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis. <i>Aging</i> , 2021, 13, 450-459.	1.4	14
1197	Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology. <i>Oncotarget</i> , 2017, 8, 106167-106168.	0.8	25
1198	Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition. <i>Oncotarget</i> , 2018, 9, 29587-29600.	0.8	18
1199	Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity. <i>Oncotarget</i> , 2018, 9, 30115-30127.	0.8	25
1200	Computational analysis of data from a genome-wide screening identifies new PARP1 functional interactors as potential therapeutic targets. <i>Oncotarget</i> , 2019, 10, 2722-2737.	0.8	11
1201	Differential gene expression and AKT targeting in triple negative breast cancer. <i>Oncotarget</i> , 2019, 10, 4356-4368.	0.8	14
1202	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. <i>Oncotarget</i> , 2020, 11, 1-14.	0.8	1
1203	Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line. <i>Oncotarget</i> , 2020, 11, 1653-1665.	0.8	4
1204	PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. , 2019, 2, 665-679.		20
1205	Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology. , 2019, 2, 608-617.		3
1206	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1603-1603.	0.7	8
1207	Biliary tract cancer prognostic and predictive genomics. <i>Chinese Clinical Oncology</i> , 2019, 8, 42-42.	0.4	15
1208	Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 370-382.	0.7	18
1209	Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer. <i>Current Cancer Drug Targets</i> , 2020, 20, 586-602.	0.8	78
1210	Recent Progress and Development of Small Molecule Kinase Inhibitors for the Treatment of Breast Cancer. <i>Current Enzyme Inhibition</i> , 2020, 16, 4-19.	0.3	3

#	ARTICLE	IF	CITATIONS
1211	Olaparib for advanced breast cancer. <i>Future Oncology</i> , 2020, 16, 717-732.	1.1	8
1212	Place des CTC et de l'ADN circulant dans la prise en charge du cancer du sein. <i>Oncologie</i> , 2019, 21, 40-48.	0.2	1
1213	Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer. <i>Einstein (Sao Paulo, Brazil)</i> , 2019, 17, eAO3434.	0.3	7
1214	PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation. <i>Cancers</i> , 2020, 12, 394.	1.7	91
1215	Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1290.	1.8	10
1216	HSulf and palbociclib exert synergistic antitumor effects on ER-positive triple-negative breast cancer. <i>International Journal of Oncology</i> , 2020, 57, 223-236.	1.4	8
1217	Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer. <i>International Journal of Oncology</i> , 2020, 57, 277-288.	1.4	33
1218	Triple-negative breast cancer therapy: Current and future perspectives (Review). <i>International Journal of Oncology</i> , 2020, 57, 1245-1261.	1.4	196
1219	Mainstreaming genetic counseling for BRCA testing into oncology clinics – Indian perspective. <i>Indian Journal of Cancer</i> , 2019, 56, 38.	0.2	9
1220	Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 265-275.	0.4	15
1221	Risks and protective factors for triple negative breast cancer with a focus on micronutrients and infections. <i>Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia</i> , 2018, 162, 83-89.	0.2	9
1222	Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, .	0.2	18
1223	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 452-478.	2.3	848
1224	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 380-391.	2.3	314
1225	A Web-Based Tool to Automate Portions of Pretest Genetic Counseling for Inherited Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 841-847.	2.3	18
1226	“Lazarus Response” to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion. <i>Cureus</i> , 2018, 10, e2150.	0.2	5
1227	Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer. <i>Cureus</i> , 2019, 11, e5197.	0.2	4
1228	Metastatic Breast Cancer. <i>UNIPA Springer Series</i> , 2021, , 467-479.	0.1	0

#	ARTICLE	IF	CITATIONS
1229	Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 1008.	1.7	9
1230	Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 662055.	1.3	12
1231	IMProving care After inherited Cancer Testing (IMPACT) study: protocol of a randomized trial evaluating the efficacy of two interventions designed to improve cancer risk management and family communication of genetic test results. <i>BMC Cancer</i> , 2021, 21, 1099.	1.1	5
1232	Antibody drug conjugates for patients with breast cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100795.	1.0	3
1233	Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View. <i>Cancers</i> , 2021, 13, 5216.	1.7	15
1234	Penetrance of male breast cancer susceptibility genes: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 31-38.	1.1	10
1235	Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 61-81.	0.7	5
1236	Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1303-1311.	1.1	8
1237	Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance. <i>Biomedicines</i> , 2021, 9, 1512.	1.4	29
1238	Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders. <i>Human Cell</i> , 2022, 35, 199-213.	1.2	20
1239	Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 109-126.	0.6	9
1240	Implications of TGF β 2 Signaling and CDK Inhibition for the Treatment of Breast Cancer. <i>Cancers</i> , 2021, 13, 5343.	1.7	5
1241	Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 1721-1731.	5.1	172
1242	Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. <i>Npj Precision Oncology</i> , 2021, 5, 92.	2.3	11
1243	PARP inhibitors: clinical relevance and the role of multidisciplinary cancer teams on drug safety. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 541-551.	1.0	2
1244	Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. <i>Cancers</i> , 2021, 13, 5198.	1.7	10
1245	Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists. <i>Journal of Clinical Oncology</i> , 2021, 39, 4020-4028.	0.8	20
1246	Acknowledging Disparities in Hereditary Cancer Testing. <i>Journal of Clinical Oncology</i> , 2021, 39, 4001-4003.	0.8	2

#	ARTICLE	IF	CITATIONS
1247	De novo metastatic breast cancer arising in young women: review of the current evidence. Clinical Breast Cancer, 2021, , .	1.1	6
1248	Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis. Breast Cancer Research and Treatment, 2022, 191, 137-145.	1.1	0
1249	Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. European Journal of Medical Genetics, 2021, 64, 104350.	0.7	22
1250	Psychological Resistance to Receiving <I>BRCA2</I> Mutation-positive Resultsâ€”A Case Studyâ€”. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2018, 79, 1820-1824.	0.0	0
1251	The prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case.. Meditsinskiy Sovet, 2018, , 49-55.	0.1	0
1252	Molecular Targeting Agents for Breast Cancer. Nihon Ika Daigaku Igakkai Zasshi, 2018, 14, 180-182.	0.0	0
1253	Systemic Treatment Drugs and Regimens. , 2019, , 587-608.		0
1255	Clinical Advances in the Treatment of Metastatic Triple Negative Breast Cancer. Advances in Clinical Medicine, 2019, 09, 871-876.	0.0	0
1256	Systemic Treatment Drugs/Regimens and Dose Modifications. , 2019, , 789-801.		0
1257	PARP Inhibiter as a Treatment for Breast Cancer. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq1 1 0.784314 rgBT /Overl	0.0	0
1258	Hereditary Breast Cancer : The Difference between Genetic Medicines of Hereditary Cancer Syndrome and Genetic Testing as Companion Diagnostics. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq0 0 0 rgBT /Overl	0.0	0
1260	Current Treatment of Febrile Neutropenia. , 2019, , 991-1006.		0
1261	Preparing for The Era of Precision Medicine to Improve Individualized Outcomes in Women with Breast Cancer. Eurasian Journal of Medicine and Oncology, 2019, , .	1.0	0
1262	Pharmacogenetic and pharmacogenomic discovery strategies. Cancer Drug Resistance (Alhambra, Calif) Tj ETQq1 1 0.784314 rgBT /Ove	0.9	5
1263	Prevalence of Germline Brca1 and Brca2 Mutation Among Filipinos. Cancer Research Journal, 2019, 7, 79.	0.0	0
1264	What is the Current Effectiveness of Olaparib for Breast Cancer Patients with a BRCA Mutation? A Systematic Review. Open Nursing Journal, 2019, 13, 39-59.	0.2	0
1266	ä¹³ç™™CEæ²»ç™™,ä«ãšãã, ä^tãe™™çšš,,è-ãf»æš-ã½“ãE»è-ãã ç³¼çššãã±ææ». Journal of Otolarngology of Japan, 2010, 122, 839		0
1268	Clinicopathological Characteristics and Survival of Triple-Negative Breast Cancer Patients: A single Institution Study from Egypt. Research in Oncology, 2019, 15, 31-34.	0.2	0

#	ARTICLE	IF	CITATIONS
1269	Evaluaci3n y Manejo del C4ncer de Mama Metast4sico, Irreseable o Recurrente: 1er Consenso Nacional del C4ncer de Mama de la Sociedad Paname4a de Oncolog4a (SPO). Revista Medica De Panama, 2019, 39, .	0.0	0
1272	Current topics in hereditary breast and ovarian cancer. Okayama Igakkai Zasshi, 2019, 131, 89-96.	0.0	1
1273	Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors. Archive of Clinical Cases, 2019, 06, 69-75.	0.1	0
1274	Outcomes of Women with Non-Metastatic Triple-Negative Breast Cancer in Oman: A single-centre experience. Sultan Qaboos University Medical Journal, 2019, 19, 209.	0.3	3
1275	Combination of Ixabepilone and Capecitabine in Metastatic Triple Negative Breast Cancer. Clinical case. Meditsinskiy Sovet, 2019, , 69-72.	0.1	0
1277	Hormone Receptor4Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices. Journal of the Advanced Practitioner in Oncology, 2020, 11, 275-279.	0.2	0
1278	PARP1 inhibitors in breast cancer therapy. Mechanism of action and clinical use. Opuholi Zenskoj Reproktivnoy Sistemoy, 2020, 16, 55-64.	0.1	0
1279	Construction of SIRT1 gene shRNA lentivirus vector and its effect on the proliferation of breast cancer cells. Cellular and Molecular Biology, 2020, 66, 204-210.	0.3	0
1282	Options for Endocrine-Refractory, Hormone Receptor4Positive Breast Cancer: Which Target and When?. Journal of Clinical Oncology, 2021, 39, 3890-3896.	0.8	0
1283	Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 742139.	1.3	8
1284	PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later. Annals of Oncology, 2021, 32, 1460-1462.	0.6	4
1285	Changing Patterns in Clinicopathological Characteristics of Breast Cancer and Prevalence of BRCA Mutations: Analysis in a Rural Area of Southern China. International Journal of General Medicine, 2021, Volume 14, 7371-7380.	0.8	3
1286	U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review. Clinical Cancer Research, 2022, 28, 1072-1086.	3.2	31
1287	BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials. Frontiers in Oncology, 2021, 11, 718871.	1.3	6
1288	Adverse events of targeted therapies approved for women's cancers. International Journal of Women's Dermatology, 2021, 7, 552-559.	1.1	0
1289	Association of Homologous Recombination4DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. Molecular Cancer Therapeutics, 2022, 21, 227-236.	1.9	4
1291	Hereditary breast cancer: review and current approach. Mastology, 0, 30, .	0.1	0
1292	Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer. Meditsinskiy Sovet, 2020, , 143-146.	0.1	1

#	ARTICLE	IF	CITATIONS
1293	Olaparib in the metastatic HER2-negative breast cancer setting. <i>Meditinskiy Sovet</i> , 2020, , 22-30.	0.1	1
1294	Microgravity: New aspect for breast cancer treatment, a review. <i>Acta Astronautica</i> , 2022, 190, 62-73.	1.7	5
1295	Development of Molecularly Targeted Agents in Early Phase Clinical Trials. , 2020, , 199-220.		0
1296	Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer. <i>Journal of Pharmacy and Nutrition Sciences (discontinued)</i> , 2020, 10, 46-59.	0.2	0
1297	Why CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer. <i>Oncology & Hematology Review</i> , 2020, 16, 23.	0.2	0
1298	Management of Advanced Breast Cancer in Young Women: Whatâ€™s New in Systemic Treatment. , 2020, , 127-142.		0
1299	A Case of Breast Cancer with Recurrent Peritoneal Dissemination Treated with Eribulin Mesilate. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)</i> , 2020, 45, 109-113.	0.0	0
1300	<i>Neue Arzneimittel 2019.</i> , 2020, , 43-150.		2
1301	Young Age and Breast Cancer Biology. , 2020, , 13-22.		0
1302	Fundamental and clinical knowledge about breast cancer predisposition syndromes. <i>Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening)</i> , 2020, 29, 1-7.	0.0	0
1303	Two Cases of HER2-negative Recurrent Breast Cancer Treated with Olaparib as a Second and Third Line of Therapy with Good Responses. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical)</i> Tj ETQq0 0 0 rgBT /Oo0lock 10Tf 50 337		0
1304	Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 9-14.	0.1	0
1306	Current and Future Directions for PARP Inhibition. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 297-300.	0.2	0
1307	Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 266-270.	0.2	0
1310	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2021, 32, 1475-1495.	0.6	454
1311	Universal genetic testing of patients with newly diagnosed breast cancer â€” ready for prime time?. <i>Medical Journal of Australia</i> , 2021, 215, 449-453.	0.8	1
1312	Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine. <i>JCO Precision Oncology</i> , 2021, 5, 1699-1708.	1.5	10
1313	The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncologyâ€”When and Why?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12089.	1.8	8

#	ARTICLE	IF	CITATIONS
1314	A Review of Breast Cancer Risk Factors in Adolescents and Young Adults. <i>Cancers</i> , 2021, 13, 5552.	1.7	7
1315	GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166300.	1.8	8
1317	Practice-Changing Interventions in the Systemic Management of Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 941-944.	2.3	0
1318	Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer. <i>Journal of Pharmacy and Nutrition Sciences (discontinued)</i> , 2020, 10, 155-168.	0.2	0
1319	Post-neoadjuvant treatment of breast cancer. <i>Meditinskiy Sovet</i> , 2020, , 232-241.	0.1	0
1320	Personomics – an innovative tool of precision medicine and its role in the individualized treatment of patients with breast cancer. <i>Asia-Pacific Journal of Oncology</i> , 2020, , 1-8.	0.2	0
1321	PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice. <i>Meditinskiy Sovet</i> , 2020, , 57-61.	0.1	0
1323	Sequencing for an interdisciplinary molecular tumor board in patients with advanced breast cancer: experiences from a case series. <i>Oncotarget</i> , 2020, 11, 3279-3285.	0.8	2
1325	The extension of 2-in-1 adaptive phase 2/3 designs and its application in oncology clinical trials. <i>Contemporary Clinical Trials</i> , 2020, 98, 106148.	0.8	4
1326	Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. <i>American Journal of Cancer Research</i> , 2018, 8, 1837-1846.	1.4	26
1327	Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a 1/2 Mutation. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 167-174.	0.2	26
1328	Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 648-661.	1.4	15
1329	Acquired multiple secondary mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a germline mutation. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 612-617.	0.0	18
1330	Somatic mutation profiling in -negative breast and ovarian cancer patients by multigene panel sequencing. <i>American Journal of Cancer Research</i> , 2020, 10, 2919-2932.	1.4	5
1331	Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. <i>Annals of Translational Medicine</i> , 2020, 8, 1389.	0.7	0
1332	The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 73-87.	0.4	4
1333	Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany. <i>Breast Care</i> , 2021, 16, 389-395.	0.8	0
1334	PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review. <i>Advances in Genetics</i> , 2021, 108, 35-80.	0.8	5

#	ARTICLE	IF	CITATIONS
1335	Epigenetics and precision medicine in prostate cancer. , 2022, , 69-108.		0
1336	Mammakarzinom. , 2022, , 340-351.		0
1337	Genetic Syndromes Associated with Gastric Cancer. Gastrointestinal Endoscopy Clinics of North America, 2022, 32, 147-162.	0.6	8
1339	Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives. Frontiers in Oncology, 2021, 11, 769280.	1.3	45
1340	The Influence of Wuzhi Capsule on the Pharmacokinetics of Cyclophosphamide. Recent Patents on Anti-Cancer Drug Discovery, 2022, 17, 195-203.	0.8	5
1341	BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review. Oncology Research and Treatment, 2022, 45, 54-61.	0.8	6
1342	Drug-Dependent Morphological Transitions in Spherical and Worm-Like Polymeric Micelles Define Stability and Pharmacological Performance of Micellar Drugs. Small, 2022, 18, e2103552.	5.2	31
1343	Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement. Cancers, 2021, 13, 5643.	1.7	16
1344	Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer. Cancers, 2021, 13, 5697.	1.7	10
1345	Treatment landscape of triple-negative breast cancer — expanded options, evolving needs. Nature Reviews Clinical Oncology, 2022, 19, 91-113.	12.5	414
1346	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. MedComm, 2021, 2, 514-530.	3.1	12
1347	The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer — a study protocol. BMC Cancer, 2021, 21, 1238.	1.1	4
1348	qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 191, 335-344.	1.1	5
1349	Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. Canadian Urological Association Journal, 2021, 16, .	0.3	2
1350	Pharmacogenomics in solid cancers and hematologic malignancies: improving personalized drug prescription. Therapie, 2021, , .	0.6	1
1352	Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. Npj Breast Cancer, 2021, 7, 142.	2.3	13
1353	Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. Cancers, 2021, 13, 5830.	1.7	19
1354	Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. European Journal of Cancer, 2021, 159, 283-295.	1.3	24

#	ARTICLE	IF	CITATIONS
1355	Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. <i>Future Oncology</i> , 2021, 17, 5013-5022.	1.1	2
1357	PARPi: Efficacy in Hereditary Breast Cancer. , 2021, , 293-312.		0
1358	Triple-negative breast cancer and basal-like subtypeâ€™...: Pathology and targeted therapy. <i>Journal of Medical Investigation</i> , 2021, 68, 213-219.	0.2	7
1360	Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110595.	1.4	10
1363	A Case of Hormone Receptor-positive Recurrent Breast Cancer in which Stable Disease Condition was Achieved by Olaparib. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2021, 82, 1084-1088.	0.0	0
1364	Combined Ultrasound Treatment with Transferrin-Coupled Nanoparticles Improves Active Targeting of 4T1 Mammary Carcinoma Cells. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110623.	0.8	5
1365	Germline Findings from Genetic Testing for Breast Cancer. , 2021, , 227-241.		0
1366	Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline <i>BRCA1</i> <i>2</i> mutations and hormone receptor status from the phase-3 BROCADE3 trial. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110596.	1.4	9
1367	Olaparib-Induced Immune-Mediated Liver Injury. <i>ACG Case Reports Journal</i> , 2022, 9, e00735.	0.2	1
1368	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. <i>Journal of Personalized Medicine</i> , 2022, 12, 72.	1.1	26
1369	Breast Cancer Immunotherapy: From Biology to Current Clinical Applications. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 113-124.	3.0	2
1372	Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. <i>Annals of Translational Medicine</i> , 2020, 8, 1389-1389.	0.7	3
1373	Survey on Physiciansâ€™ Knowledge and Training Needs in Genetic Counseling in Germany. <i>Breast Care</i> , 2021, 16, 389-395.	0.8	3
1374	Management of triple-negative breast cancer in the era of novel therapies: A narrative review. <i>Cancer Research Statistics and Treatment</i> , 2021, 4, 668.	0.1	4
1375	Updates in HER2-Positive and Triple-Negative Breast Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 605-609.	2.3	2
1376	PARP Inhibitors in Pancreatic Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 465-475.	1.0	18
1377	New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 441-456.	1.0	3
1378	Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1665.	1.8	48

#	ARTICLE	IF	CITATIONS
1380	PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. <i>Cancers</i> , 2022, 14, 599.	1.7	8
1381	Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets. <i>BMC Cancer</i> , 2022, 22, 13.	1.1	15
1382	Mapping Intellectual Structures and Research Hotspots of Triple Negative Breast Cancer: A Bibliometric Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 689553.	1.3	17
1383	Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 742833.	1.3	4
1384	Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study. <i>Cancers</i> , 2022, 14, 230.	1.7	13
1385	Q and A: A New Standard of Care for Germline <i>BRCA1</i> and/or <i>BRCA2</i> Mutation Carriers With Early-Stage Breast Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 427-429.	1.4	1
1386	Hormonal and Targeted Treatments in Breast Cancer. , 2022, , 443-463.		3
1387	Metaplastic Breast Carcinoma Revisited; Subtypes Determine Outcomes. <i>Surgical Pathology Clinics</i> , 2022, 15, 159-174.	0.7	4
1388	ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of nonapoptotic phosphatidylserine. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	7
1389	A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 599-610.	1.1	4
1390	Systemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper. <i>Journal of Geriatric Oncology</i> , 2022, , .	0.5	4
1391	Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 328-332.	0.5	4
1392	An overview of genetic services delivery for hereditary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 491-500.	1.1	12
1393	Predictive and prognostic significance of BRCAness in HER2-negative breast cancer. <i>Breast Cancer</i> , 2022, 29, 368-376.	1.3	3
1394	<i>PARP</i> mediated <i>DNA</i> damage response, genomic stability and immune responses. <i>International Journal of Cancer</i> , 2022, 150, 1745-1759.	2.3	18
1395	Is adjuvant chemotherapy necessary in older patients with breast cancer?. <i>Breast Cancer</i> , 2022, , 1.	1.3	2
1396	Value of the loss of heterozygosity to <i>BRCA1</i> variant classification. <i>Npj Breast Cancer</i> , 2022, 8, 9.	2.3	2
1397	Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 2882-2894.	0.7	20

#	ARTICLE	IF	CITATIONS
1398	Updates on breast biomarkers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 163-176.	1.4	33
1399	Perspectives on the role of breast cancer susceptibility gene in breast cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 495-511.	1.0	1
1400	Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 616.	1.0	6
1401	Real-world multi-country study of <i>BRCA1/2</i> mutation testing among adult women with HER2-negative advanced breast cancer. <i>Future Oncology</i> , 2022, 18, 1089-1101.	1.1	3
1402	A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer. <i>Surgical Pathology Clinics</i> , 2022, 15, 105-120.	0.7	6
1403	Systemic therapy for triple-negative breast cancer: A changing landscape. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103608.	2.0	0
1404	Eligibility Criteria Can Be Deceiving: How Direct and Indirect Exclusion Criteria Affects Recruitment of Under-Served Groups in Breast Cancer Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1405	Biomarkers of everolimus efficacy in breast cancer therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522110736.	0.5	2
1406	The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 331.	1.1	3
1407	Brain metastasis in de novo breast cancer: An updated population-level study from SEER database. <i>Asian Journal of Surgery</i> , 2022, 45, 2259-2267.	0.2	8
1408	BRCA1 Norway: comparison of classification for BRCA1 germline variants detected in families with suspected hereditary breast and ovarian cancer between different laboratories. <i>Familial Cancer</i> , 2022, 21, 389-398.	0.9	2
1409	Oleanolic Acid (OA) Targeting UNC5B Inhibits Proliferation and EMT of Ovarian Cancer Cell and Increases Chemotherapy Sensitivity of Niraparib. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	2
1410	Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?. <i>Cancers</i> , 2022, 14, 482.	1.7	21
1411	Monitoring and personalization in treatment of breast cancer patients with metastatic bone lesions. <i>EUREKA Health Sciences</i> , 2022, , 37-48.	0.1	0
1412	Circulating Tumor Cell Kinetics and Morphology from the Liquid Biopsy Predict Disease Progression in Patients with Metastatic Colorectal Cancer Following Resection. <i>Cancers</i> , 2022, 14, 642.	1.7	3
1413	Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience. <i>Journal of Personalized Medicine</i> , 2022, 12, 195.	1.1	1
1415	Protective Effect of Minocycline Hydrochloride on the Mouse Embryonic Development Against Suboptimal Environment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 799042.	1.8	1
1416	Advances in cGAS-STING Signaling Pathway and Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 800393.	1.8	7

#	ARTICLE	IF	CITATIONS
1417	Increase in ADAR1p110 activates the canonical Wnt signaling pathway associated with aggressive phenotype in triple negative breast cancer cells. <i>Gene</i> , 2022, 819, 146246.	1.0	4
1418	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. <i>Cancer Treatment Reviews</i> , 2022, 104, 102337.	3.4	6
1419	“It was an important part of my treatment” a qualitative study of Norwegian breast Cancer patients’ experiences with mainstreamed genetic testing. <i>Hereditary Cancer in Clinical Practice</i> , 2022, 20, 6.	0.6	3
1420	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1493-1499.	3.2	22
1421	Emerging Biomarkers for Diagnosis, Prevention and Treatment of Brain Metastases”From Biology to Clinical Utility. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 11.	1.0	1
1422	<i>BRCA&/i>; associated prostate cancer. <i>BRCA&/i>; heredity of one family. <i>Onkourologiya</i> , 2022, 17, 157-164.	0.1	0
1423	SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients. <i>Endocrine Oncology</i> , 2022, , .	0.1	0
1424	Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2022, 23, 393-405.	5.1	16
1425	Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy. <i>Frontiers in Immunology</i> , 2022, 13, 826577.	2.2	3
1426	Hereditary Breast and Ovarian Cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, 49, 117-147.	0.7	3
1427	The role of PARP inhibitors in gastrointestinal cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103621.	2.0	7
1428	HLA Class II Histocompatibility Antigen $\hat{3}$ Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer. <i>Cancers</i> , 2021, 13, 6179.	1.7	7
1429	Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103539.	2.0	11
1430	Emerging treatment strategies for metastatic triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210869.	1.4	15
1431	Psychosocial outcome and health behaviour intent of breast cancer patients with BRCA1/2 and PALB2 pathogenic variants unselected by a priori risk. <i>PLoS ONE</i> , 2022, 17, e0263675.	1.1	0
1432	New insights into the discovery of drugs for triple-negative breast cancer metastasis. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 365-376.	2.5	3
1433	Breast cancer management in 2021: A primer for the obstetrics and gynecology. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 82, 30-45.	1.4	18
1434	The Role of Keratin17 in Human Tumours. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818416.	1.8	11

#	ARTICLE	IF	CITATIONS
1435	RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?. Expert Review of Molecular Diagnostics, 2022, 22, 185-199.	1.5	16
1436	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. Cancers, 2022, 14, 1253.	1.7	69
1437	Genetic medicine is accelerating in Japan. Breast Cancer, 2022, 29, 659-665.	1.3	5
1438	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. Cancers, 2022, 14, 1003.	1.7	18
1439	Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. Cancers, 2022, 14, 953.	1.7	16
1440	Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers. Annals of Surgical Oncology, 2022, 29, 3578-3590.	0.7	9
1441	Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy. Current Cancer Drug Targets, 2022, 22, 530-536.	0.8	4
1442	Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses. Cancers, 2022, 14, 997.	1.7	2
1443	Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer. Cureus, 2022, 14, e22575.	0.2	2
1444	Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells. Frontiers in Oncology, 2022, 12, 819714.	1.3	2
1445	Molecular profiling leading to personalized treatment in breast cancer. Memo - Magazine of European Medical Oncology, 0, , 1.	0.3	1
1446	Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer. Frontiers in Oncology, 2022, 12, 842705.	1.3	9
1447	Implementation of patient-reported outcome measures into health care for men with localized prostate cancer. Nature Reviews Urology, 2022, 19, 263-279.	1.9	5
1449	Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy. Frontiers in Immunology, 2022, 13, 837293.	2.2	23
1450	High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers. Journal of Clinical Medicine, 2022, 11, 1605.	1.0	2
1451	Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase Tj ETQq1 1 0,784314 rgBT /Overle	0.6	9
1452	Artificial Intelligence-Assisted Serial Analysis of Clinical Cancer Genomics Data Identifies Changing Treatment Recommendations and Therapeutic Targets. Clinical Cancer Research, 2022, 28, 2361-2372.	3.2	2
1453	Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy. International Journal of Molecular Sciences, 2022, 23, 3238.	1.8	14

#	ARTICLE	IF	CITATIONS
1454	PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patientsâ€™ CTCs. <i>Cancers</i> , 2022, 14, 1731.	1.7	7
1455	Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database. <i>Hereditas</i> , 2022, 159, 18.	0.5	4
1456	Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 43.	2.3	1
1457	Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening. <i>Frontiers in Oncology</i> , 2022, 12, 755053.	1.3	12
1458	Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes. <i>JCO Precision Oncology</i> , 2022, 6, e2100140.	1.5	14
1459	Sequencing of <i>BRCA1/2</i> -alterations using NGS-based technology: annotation as a challenge. <i>Oncotarget</i> , 2022, 13, 464-475.	0.8	0
1460	Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown, <i>BRCA1/2</i> Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and four EU Countries. <i>Breast Care</i> , 2022, 17, 460-469.	0.8	3
1461	pH-Responsive Hyaluronic Acid Nanoparticles for Enhanced Triple Negative Breast Cancer Therapy. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 1437-1457.	3.3	10
1462	A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2892.	1.8	3
1464	Underserved groups remain underserved as eligibility criteria routinely exclude them from breast cancer trials. <i>Journal of Clinical Epidemiology</i> , 2022, 147, 132-141.	2.4	5
1465	New Advances in Targeted Therapy of HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 828438.	1.3	7
1466	Protective effects of a SIRT1 inhibitor on primordial follicle activation and growth induced by cyclophosphamide: insights from a bovine in vitro folliculogenesis system. <i>Journal of Assisted Reproduction and Genetics</i> , 2022, 39, 933-943.	1.2	2
1467	Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 176, 103642.	2.0	4
1468	STAMBPL1 promotes breast cancer cell resistance to cisplatin partially by stabilizing MKP-1 expression. <i>Oncogene</i> , 2022, 41, 2265-2274.	2.6	7
1469	High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 49-63.	1.1	8
1470	PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. <i>Journal of Clinical Medicine</i> , 2022, 11, 1734.	1.0	5
1471	PARP Inhibitors Resistance: Mechanisms and Perspectives. <i>Cancers</i> , 2022, 14, 1420.	1.7	22
1472	Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma. <i>Cell Communication and Signaling</i> , 2022, 20, 39.	2.7	0

#	ARTICLE	IF	CITATIONS
1473	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. <i>ESMO Open</i> , 2022, 7, 100409.	2.0	25
1474	PARP inhibition in breast cancer: progress made and future hopes. <i>Npj Breast Cancer</i> , 2022, 8, 47.	2.3	42
1475	Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1094-1102.	0.5	4
1476	Identification and Management of Pathogenic Variants in <i>BRCA1</i> , <i>BRCA2</i> , and <i>PALB2</i> in a Tumor-Only Genomic Testing Program. <i>Clinical Cancer Research</i> , 2022, 28, 2349-2360.	3.2	8
1477	Epigenomic alterations in cancer: mechanisms and therapeutic potential. <i>Clinical Science</i> , 2022, 136, 473-492.	1.8	4
1478	Incidence and impact of brain metastasis in patients with hereditary <i>BRCA1</i> or <i>BRCA2</i> mutated invasive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 46.	2.3	10
1479	A phase I study of talazoparib (NCT03673673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCT03673673). <i>Cancer Medicine</i> , 2022, 11, 3969-3981.	1.3	11
1480	Atrial fibrillation. <i>Nature Reviews Disease Primers</i> , 2022, 8, 21.	18.1	126
1481	Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 3461-3471.	0.3	2
1482	Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. <i>European Journal of Cancer</i> , 2022, 166, 87-99.	1.3	21
1483	Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 482-490.	1.0	0
1484	Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic <i>BRCA1/2</i> Mutations or Mutations in Non- <i>BRCA1/2</i> , DNA Damage Repair Genes. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	6
1485	Fine-Needle Aspiration Is Suitable for Breast Cancer <i>BRCA</i> Molecular Assessment: A Case Report. <i>Journal of Molecular Pathology</i> , 2021, 2, 319-324.	0.5	0
1486	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. <i>Cancers</i> , 2021, 13, 6385.	1.7	19
1488	Peculiarities of <i>BRCA1/2</i> testing in patients with advanced HER2-negative breast cancer in the Russian Federation (results of a survey of Russian oncologists). <i>Malignant Tumours</i> , 2021, 11, 38-44.	0.1	0
1489	Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 790967.	1.3	2
1490	The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers. <i>Journal of Hematology and Oncology</i> , 2021, 14, 206.	6.9	24
1491	Homologous Recombination Deficiencies and Hereditary Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 348.	1.8	27

#	ARTICLE	IF	CITATIONS
1492	Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape. <i>Cancers</i> , 2022, 14, 44.	1.7	16
1493	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 141-153.	1.1	5
1494	Effectiveness of combination with eribulin in third line of chemotherapy for triple negative breast cancer (case report). <i>Medical Alphabet</i> , 2021, 1, 20-24.	0.0	0
1495	Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 60-78.	1.0	5
1496	PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer?. <i>Ecancermedalscience</i> , 2021, 15, ed118.	0.6	4
1497	Real-World Outcome of Platinum-Based Chemotherapy in Advanced Breast Cancer (ABC): A Retrospective Study from a Tertiary Cancer Center in India. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.1	0
1498	Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 1270.	1.7	5
1499	Lebensqualität und Lebensverlängerung durch endokrin kombinierte Tumorthherapie. <i>Frauenheilkunde Up2date</i> , 2021, 15, 497-513.	0.0	0
1500	PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 762989.	2.2	15
1501	Current state of clinical development of TROP2-directed antibody-drug conjugates for triple-negative breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2022, 15, 129-132.	0.3	3
1502	Triple negative breast cancer: any closer to cracking the code?. <i>Current Opinion in Obstetrics and Gynecology</i> , 2022, 34, 52-55.	0.9	4
1503	Psychosocial impact of proactive rapid genetic counseling following breast cancer diagnosis. <i>Psycho-Oncology</i> , 2022, 31, 788-797.	1.0	0
1504	Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 23435.	1.6	10
1505	Update Mammakarzinom 2021 Teil 1 – Prävention und frühe Krankheitsstadien. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021, 18, 377-390.	0.0	0
1506	Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. <i>Cancer Research</i> , 2022, 82, 1646-1657.	0.4	40
1507	Male Breast Cancer: From Molecular Genetics to Clinical Management. <i>Cancers</i> , 2022, 14, 2006.	1.7	13
1508	PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 607-631.	1.9	20
1509	Tumor genetics and individualized therapy. <i>Der Gynakologe</i> , 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
1510	An Exposureâ€Response Model with Timeâ€Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCAâ€Mutated Advanced Breast Cancer (BROCADE3) Trial. <i>Journal of Clinical Pharmacology</i> , 2022, , .	1.0	3
1511	Physiological levels of poly(ADP-ribose) during the cell cycle regulate HeLa cell proliferation. <i>Experimental Cell Research</i> , 2022, 417, 113163.	1.2	4
1513	Targeting mutations in cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	56
1514	Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	6
1515	Genome editing: An essential technology for cancer treatment. <i>Medicine in Omics</i> , 2022, , 100015.	0.6	3
1519	Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study. <i>Breast Cancer</i> , 2022, 29, 796-807.	1.3	2
1520	Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 633-644.	1.9	2
1521	Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies. <i>Expert Review of Proteomics</i> , 2022, 19, 115-129.	1.3	3
1522	An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2022, 48, 760-770.	0.7	2
1523	MicroRNA-199a-3p promotes drug sensitivity in triple negative breast cancer by down-regulation of .. <i>American Journal of Translational Research (discontinued)</i> , 2022, 14, 2021-2036.	0.0	0
1524	Targeting biologically specific molecules in triple negative breast cancer (TNBC). , 2022, , 177-200.		7
1525	Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2022, 13, 2226-2237.	1.2	2
1526	Binding Sites of Anticancer Drugs on Human Serum Albumin (HSA): A Review. <i>Protein and Peptide Letters</i> , 2022, 29, 651-675.	0.4	10
1527	Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. <i>Cells</i> , 2022, 11, 1466.	1.8	6
1528	PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives. <i>Cancers</i> , 2022, 14, 2161.	1.7	15
1530	DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. <i>Cells</i> , 2022, 11, 1463.	1.8	3
1531	Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors. <i>Genes</i> , 2022, 13, 803.	1.0	2
1532	Attitudes and training needs of oncologists and surgeons in mainstreaming breast cancer genetic counseling in a lowâ€toâ€middle income Asian country. <i>Journal of Genetic Counseling</i> , 2022, 31, 1080-1089.	0.9	4

#	ARTICLE	IF	CITATIONS
1533	Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cell-derived explants. <i>JCI Insight</i> , 2022, , .	2.3	5
1534	Causes of resistance to PARP inhibitors and ways to overcome it. Case report of aggressive <i>BRCA</i>-related breast cancer. <i>Opuholi Zenskoj Reproktivnoj Sistemy</i> , 2022, 18, 54-65.	0.1	1
1535	Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2405.	1.7	1
1536	Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland. <i>Prostate International</i> , 2022, 10, 142-147.	1.2	4
1537	Incidence of grade 3—4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 235-240.	1.5	6
1538	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, 64.	2.3	3
1540	Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 113-123.	1.0	10
1542	Triple-Negative Breast Cancer: the Current Aspects of Pathogenesis and Therapies. <i>BioNanoScience</i> , 2022, 12, 1404-1435.	1.5	2
1543	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. <i>Cancers</i> , 2022, 14, 2470.	1.7	4
1544	Pharmacogenetic Review: Germline Genetic Variants Possessing Increased Cancer Risk With Clinically Actionable Therapeutic Relationships. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	1
1545	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	2.0	26
1546	Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. <i>European Journal of Cancer</i> , 2022, 170, 73-84.	1.3	10
1547	Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside. <i>Cancer Treatment Reviews</i> , 2022, 108, 102417.	3.4	11
1548	Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 47-59.	1.8	8
1549	The History of Early Breast Cancer Treatment. <i>Genes</i> , 2022, 13, 960.	1.0	16
1550	STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	68
1551	Efficacy of Clinical Guidelines in Identifying All Japanese Patients with Hereditary Breast and Ovarian Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6182.	1.2	0
1552	Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). <i>Cancers</i> , 2022, 14, 2569.	1.7	94

#	ARTICLE	IF	CITATIONS
1553	Molecular subtyping of small cell lung cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 450-462.	4.3	20
1554	Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy. <i>Hepatology Communications</i> , 2022, 6, 2474-2487.	2.0	6
1556	Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. <i>Cancer Letters</i> , 2022, 547, 215775.	3.2	7
1557	Clinical outcomes of curative-intent multimodal management of chemorefractory nonmetastatic inflammatory breast cancer. <i>Strahlentherapie Und Onkologie</i> , 0, , .	1.0	0
1558	Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. <i>Oncogene</i> , 2022, 41, 3498-3506.	2.6	9
1559	Talazoparib in BRCA-mutated advanced breast cancer: is earlier better?. <i>Pharmacogenomics</i> , 2022, 23, 487-492.	0.6	0
1561	A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	1
1562	To resect or not to resect? the dilemma in oligometastatic breast cancer. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, .	0.7	0
1563	Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. <i>NAR Cancer</i> , 2022, 4, .	1.6	10
1564	Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 808-824.	1.8	2
1565	Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors. <i>Targeted Oncology</i> , 2022, 17, 355-368.	1.7	1
1566	Targeting euchromatic histone lysine methyltransferases sensitizes colorectal cancer to histone deacetylase inhibitors. <i>International Journal of Cancer</i> , 0, , .	2.3	2
1567	Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer. <i>Journal of Drug Targeting</i> , 0, , 1-18.	2.1	7
1571	Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	5
1572	The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 723-734.	2.3	19
1573	Breast Cancer Genomics: Primary and Most Common Metastases. <i>Cancers</i> , 2022, 14, 3046.	1.7	3
1574	Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	0
1575	Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. <i>Clinical Cancer Research</i> , 2022, 28, 3669-3676.	3.2	3

#	ARTICLE	IF	CITATIONS
1576	Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis. <i>Cells</i> , 2022, 11, 1857.	1.8	10
1577	Clinical relevance of receptor conversion in metastatic breast cancer. <i>Medicine (United States)</i> , 2022, 101, e29136.	0.4	3
1578	A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial). <i>Annals of Surgical Oncology</i> , 0, , .	0.7	3
1579	Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer. <i>Journal of Investigative Medicine</i> , 2022, 70, 1329-1341.	0.7	2
1580	Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 717-723.	1.1	1
1581	Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer. <i>Journal of Cellular and Molecular Medicine</i> , 0, , .	1.6	1
1582	Circulating tumor DNA: current challenges for clinical utility. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	50
1583	Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. <i>Clinical Obstetrics and Gynecology</i> , 2022, 65, 461-481.	0.6	6
1584	Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation. <i>Cancer Research and Treatment</i> , 2023, 55, 155-166.	1.3	1
1585	Experience with olaparib in a patient with luminal HER2-positive metastatic breast cancer. <i>Meditsinskiy Sovet</i> , 2022, , 179-184.	0.1	0
1586	Preclinical Evaluation of Ixabepilone in Combination with VEGF Receptor and PARP Inhibitors in Taxane-Sensitive and Taxane-Resistant MDA-MB-231 Breast Cancer Cells. <i>Journal of Pharmaceutical Sciences</i> , 2022, , .	1.6	0
1587	Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers. <i>British Journal of Cancer</i> , 2022, 127, 1123-1132.	2.9	3
1588	Breast Cancer with Low Recurrence Score on Oncotype DX®: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation. <i>Oncology and Therapy</i> , 0, , .	1.0	0
1589	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. <i>Cancers</i> , 2022, 14, 2950.	1.7	9
1590	Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. <i>Breast</i> , 2022, 65, 32-40.	0.9	25
1591	Cancer treatment and survivorship statistics, 2022. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 409-436.	157.7	897
1592	Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 557-573.	1.5	5
1593	Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	12

#	ARTICLE	IF	CITATIONS
1595	Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2022, 16, 117822342211075.	0.6	2
1596	PARP Inhibitor Insensitivity to <i>BRCA1/2</i> Monoallelic Mutations in Microsatellite Instability-High Cancers. <i>JCO Precision Oncology</i> , 2022, , .	1.5	15
1597	The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point. <i>Pathology</i> , 2022, , .	0.3	0
1598	Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer. <i>Cancers</i> , 2022, 14, 3175.	1.7	6
1599	Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 3205-3221.	0.8	43
1600	Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials. <i>Journal of Market Access & Health Policy</i> , 2022, 10, .	0.8	2
1601	A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System. <i>Clinical Epidemiology</i> , 0, Volume 14, 789-802.	1.5	37
1602	Addressing the routine failure to clinically identify monogenic cases of common disease. <i>Genome Medicine</i> , 2022, 14, .	3.6	11
1603	Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study. <i>Journal of Modern Oncology</i> , 2022, 24, 221-225.	0.1	0
1604	Fertility Counseling in BRCA1/2-Mutated Women with Breast Cancer and Healthy Individuals. <i>Journal of Clinical Medicine</i> , 2022, 11, 3996.	1.0	4
1605	Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies. <i>Reproduction and Fertility</i> , 2022, 3, R147-R162.	0.6	14
1606	Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation. <i>Cancers</i> , 2022, 14, 3266.	1.7	3
1607	Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 855-874.	1.9	2
1608	Predictive biomarkers for personalized medicine in breast cancer. <i>Cancer Letters</i> , 2022, 545, 215828.	3.2	14
1609	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2022, 33, 750-768.	0.6	204
1611	Reconsidering the mechanisms of action of <i>PARP</i> inhibitors based on clinical outcomes. <i>Cancer Science</i> , 2022, 113, 2943-2951.	1.7	11
1612	Characteristics of breast cancer patients tested for germline <i>BRCA1/2</i> mutations by next-generation sequencing in Ramathibodi Hospital, Mahidol University. <i>Cancer Reports</i> , 2023, 6, .	0.6	4
1613	The landscape of systemic therapy for early stage triple-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1291-1303.	0.9	4

#	ARTICLE	IF	CITATIONS
1614	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3929-3939.	0.8	66
1615	Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7481.	1.8	12
1616	Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer. <i>Current Oncology</i> , 2022, 29, 4748-4767.	0.9	9
1617	Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1618	Breast cancer brain metastasis: Current evidence and future directions. <i>Cancer Medicine</i> , 2023, 12, 1007-1024.	1.3	18
1619	Comparison of Adverse Reactions Caused by Olaparib for Different Indications. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1620	Guiding ATR and PARP inhibitor combinations with chemogenomic screens. <i>Cell Reports</i> , 2022, 40, 111081.	2.9	21
1621	CACA Guidelines for Holistic Integrative Management of Breast Cancer. , 2022, 1, .		2
1622	Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma. <i>Communications Medicine</i> , 2022, 2, .	1.9	5
1624	Clinical trials of immunotherapy in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 1-15.	1.1	19
1625	Leptomeningeal Metastases: New Opportunities in the Modern Era. <i>Neurotherapeutics</i> , 2022, 19, 1782-1798.	2.1	9
1626	Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis. <i>ESMO Open</i> , 2022, 7, 100531.	2.0	9
1627	Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study. <i>EClinicalMedicine</i> , 2022, 51, 101567.	3.2	3
1629	Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1630	Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants. <i>OncoTargets and Therapy</i> , 0, Volume 15, 815-826.	1.0	4
1631	Current State of Cell Therapies for Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 301-309.	1.0	5
1632	Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. , 2022, 237, 108253.		52
1633	<scp>CYP2S1</scp> and <scp>CYP2W1</scp> expression is associated with patient survival in breast cancer. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 550-566.	1.3	2

#	ARTICLE	IF	CITATIONS
1634	Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment. <i>Cancer Cell International</i> , 2022, 22, .	1.8	3
1635	The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1636	The Differential Metabolic Signature of Breast Cancer Cellular Response to Olaparib Treatment. <i>Cancers</i> , 2022, 14, 3661.	1.7	4
1637	Functional assessment of missense variants of uncertain significance in the cancer susceptibility gene PALB2. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	1
1638	Hematological toxicities in <scp>PARP</scp> inhibitors: A real-world study using <scp>FDA</scp> adverse event reporting system (<scp>FAERS</scp>) database. <i>Cancer Medicine</i> , 2023, 12, 3365-3375.	1.3	18
1639	PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8412.	1.8	19
1640	Discovery of a Highly Potent and Selective Dual PROTAC Degradator of CDK12 and CDK13. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 11066-11083.	2.9	18
1641	Panitumumab-DOTA- ¹¹¹ In: An Epidermal Growth Factor Receptor Targeted Theranostic for SPECT/CT Imaging and Meitner- ²²⁵ Ac Auger Electron Radioimmunotherapy of Triple-Negative Breast Cancer. <i>Molecular Pharmaceutics</i> , 2022, 19, 3652-3663.	2.3	3
1642	A PARP1-related prognostic signature constructing and PARP-1 inhibitors screening for glioma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
1643	Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors. <i>International Journal of Toxicology</i> , 0, , 109158182211213.	0.6	0
1644	Synthetic lethality in personalized cancer therapy. <i>Genome Instability & Disease</i> , 0, , .	0.5	0
1645	Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. <i>Biomarkers</i> , 2022, 27, 764-772.	0.9	5
1648	Triple negative breast cancer: approved treatment options and their mechanisms of action. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3701-3719.	1.2	13
1649	Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients. <i>Genome Medicine</i> , 2022, 14, .	3.6	11
1650	Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 243-252.	1.0	1
1651	Opportunities, obstacles and current challenges of flavonoids for luminal and triple-negative breast cancer therapy. <i>European Journal of Medicinal Chemistry Reports</i> , 2022, , 100077.	0.6	0
1652	Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board. <i>Oncologist</i> , 2023, 28, 33-39.	1.9	2
1653	Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer. <i>Cancer Prevention Research</i> , 2022, 15, 791-802.	0.7	3

#	ARTICLE	IF	CITATIONS
1654	Development and validation of a novel endoplasmic reticulum stress-related lncRNA prognostic signature and candidate drugs in breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
1655	Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents. <i>Cancers</i> , 2022, 14, 4064.	1.7	11
1656	The impact of Angiopoietin-2 genetic polymorphisms on susceptibility for malignant breast neoplasms. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
1657	A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland. <i>Familial Cancer</i> , 2023, 22, 135-149.	0.9	2
1658	Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer – A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
1659	Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1343-1360.	0.5	3
1660	Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 597-617.	2.7	6
1661	Targeted therapy for breast cancer: An overview of drug classes and outcomes. <i>Biochemical Pharmacology</i> , 2022, 204, 115209.	2.0	38
1662	Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. <i>EClinicalMedicine</i> , 2022, 52, 101595.	3.2	14
1663	Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. <i>Breast</i> , 2022, 65, 145-150.	0.9	6
1664	Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?. <i>Cancer Treatment Reviews</i> , 2022, 110, 102459.	3.4	9
1665	The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166515.	1.8	4
1667	Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer. <i>JCO Precision Oncology</i> , 2022, , .	1.5	12
1668	Nanoparticle-based Olaparib delivery enhances its effect, and improves drug sensitivity to cisplatin in triple negative breast cancer. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103731.	1.4	1
1669	Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors. <i>Gene</i> , 2022, 847, 146881.	1.0	2
1670	DNA damage, metabolism, and epigenetic regulation. , 2022, , 111-138.		0
1671	Prognostic Significance of Low HER2 Expression in Patients With Metastatic Hormone Receptor-positive Breast Cancer Treated With First Line CDK4/6 Inhibitors: A Greek Multicenter Real-world Data Analysis. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 585-591.	0.3	7
1672	Detection of <i>BRCA1</i> , <i>BRCA2</i> , and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. <i>Clinical Cancer Research</i> , 2023, 29, 81-91.	3.2	19

#	ARTICLE	IF	CITATIONS
1673	Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset. <i>Life</i> , 2022, 12, 1355.	1.1	2
1674	The pathological and clinical landscape of refractory metastatic triple negative breast cancer: a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 907-907.	0.7	1
1675	Diagnostic Value of Endoscopic Narrow-Band Imaging Technique in Early Gastric Cancer and Precancerous Lesions. <i>Scanning</i> , 2022, 2022, 1-6.	0.7	3
1676	Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 4714-4723.	3.2	15
1677	Survival outcomes of metastatic breast cancer patients by germline <i>BRCA1/2</i> status in a large multicenter real-world database. <i>International Journal of Cancer</i> , 2023, 152, 921-931.	2.3	3
1678	Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfILER-01 Trial. <i>Journal of Personalized Medicine</i> , 2022, 12, 1595.	1.1	3
1679	Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome. <i>Cancers</i> , 2022, 14, 4717.	1.7	1
1680	Dichloro{4-(4-chlorophenoxy)phthalazin-1-yl} methylphosphonic dichloride. <i>MolBank</i> , 2022, 2022, M1439.	0.2	0
1681	Homeostases of epidermis and hair follicle, and development of basal cell carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188795.	3.3	5
1682	Germline Variants in 32 Cancer-Related Genes among 700 Chinese Breast Cancer Patients by Next-Generation Sequencing: A Clinic-Based, Observational Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11266.	1.8	1
1683	Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	35
1684	Bench to bedside: research influencing clinical practice in breast cancer. <i>Diagnostic Histopathology</i> , 2022, 28, 473-479.	0.2	2
1686	Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	5
1687	Breast cancer: an update review and future perspectives. <i>Cancer Communications</i> , 2022, 42, 913-936.	3.7	70
1688	Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer. <i>JAMA Network Open</i> , 2022, 5, e2232787.	2.8	10
1690	Genomics to select treatment for patients with metastatic breast cancer. <i>Nature</i> , 2022, 610, 343-348.	13.7	57
1691	Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. <i>Future Oncology</i> , 2022, 18, 3701-3711.	1.1	3
1692	Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 40-49.	3.2	3

#	ARTICLE	IF	CITATIONS
1693	The Role of Race and Insurance Status in Access to Genetic Counseling and Testing Among High-Risk Breast Cancer Patients. <i>Oncologist</i> , 2022, 27, 832-838.	1.9	11
1694	Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report. <i>Medicine (United States)</i> , 2022, 101, e30719.	0.4	5
1695	A two-step mechanism governing PARP1-DNA retention by PARP inhibitors. <i>Science Advances</i> , 2022, 8, .	4.7	13
1696	Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1697	PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond. <i>Cancers</i> , 2022, 14, 4332.	1.7	17
1698	Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. <i>OncoImmunology</i> , 2022, 11, .	2.1	28
1699	A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA Expression. <i>Life</i> , 2022, 12, 1517.	1.1	4
1700	Targeting the DNA damage response in pediatric malignancies. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-15.	1.1	0
1702	Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11046.	1.8	19
1703	Emerging Targeted Therapies for Early Breast Cancer. <i>Drugs</i> , 2022, 82, 1437-1451.	4.9	5
1704	A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer. <i>BMC Medicine</i> , 2022, 20, .	2.3	11
1705	DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1658-1669.	3.2	28
1706	CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer. <i>Cancer Letters</i> , 2022, 551, 215944.	3.2	1
1707	Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1708	Multi-target direct-acting SARS-CoV-2 antivirals against the nucleotide-binding pockets of virus-specific proteins. <i>Virology</i> , 2022, 577, 1-15.	1.1	6
1709	Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations. <i>British Journal of Cancer</i> , 2022, 127, 1963-1973.	2.9	2
1710	Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 111, 102468.	3.4	10
1711	Clinical Relevance of BRCA1/2 Pathogenic Variants and Impaired DNA Repair Pathways in Ovarian Carcinomas. <i>Comprehensive Gynecology and Obstetrics</i> , 2022, , 59-76.	0.0	0

#	ARTICLE	IF	CITATIONS
1712	Machine Learning Methods for Survival Analysis with Clinical and Transcriptomics Data of Breast Cancer. <i>Methods in Molecular Biology</i> , 2023, , 325-393.	0.4	3
1714	Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 1802.	3.4	18
1715	PARP-inhibition reprograms macrophages toward an anti-tumor phenotype. <i>Cell Reports</i> , 2022, 41, 111462.	2.9	14
1716	Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2â€™Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel. <i>Breast</i> , 2022, 66, 236-244.	0.9	1
1717	The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer. <i>Cancers</i> , 2022, 14, 5305.	1.7	3
1718	Rare Germline <i>ATM</i> Variants Influence the Development of Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2023, 41, 1116-1128.	0.8	4
1719	Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy. <i>Pharmacological Research</i> , 2022, 186, 106529.	3.1	13
1720	Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. <i>Current Oncology Reports</i> , 2022, 24, 1801-1819.	1.8	7
1721	The Present and Future of Clinical Management in Metastatic Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 5891.	1.0	7
1722	Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	9
1723	SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. <i>Journal of Thoracic Oncology</i> , 2023, 18, 31-46.	0.5	28
1724	A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. <i>Nature Cancer</i> , 2022, 3, 1181-1191.	5.7	42
1725	Moderate-Risk Genes for Hereditary Ovarian Cancers Involved in the Homologous Recombination Repair Pathway. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11790.	1.8	3
1726	Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 4829.	1.7	8
1727	Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications. <i>Current Oncology Reports</i> , 2022, 24, 1791-1800.	1.8	1
1728	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
1729	Breast cancer liver metastasis: time to resection and criteria. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 749-751.	0.7	1
1730	Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	8

#	ARTICLE	IF	CITATIONS
1731	Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	6
1732	A patient with stage IIIB advanced breast cancer who is still alive 24 years after surgery: a case report and remarks on the treatment strategies. <i>Translational Cancer Research</i> , 2022, 11, 3903-3911.	0.4	1
1733	Gene panel testing detects important genetic alterations in ulcerative colitis-associated colorectal neoplasia. <i>Oncology Letters</i> , 2022, 24, .	0.8	0
1734	Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists' Perspective. <i>Journal of Clinical Medicine</i> , 2022, 11, 6021.	1.0	2
1735	Expanding biomarkers for PARP inhibitors. <i>Nature Cancer</i> , 2022, 3, 1141-1143.	5.7	2
1736	Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. <i>Annals of Oncology</i> , 2022, 33, 1250-1268.	0.6	128
1738	Genetics of Breast Cancer. <i>Surgical Clinics of North America</i> , 2022, , .	0.5	5
1740	Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103848.	2.0	4
1741	The European Journal of Human Genetics is turning 30: a selection of major cancer genetics papers published by the Journal. <i>European Journal of Human Genetics</i> , 2022, 30, 1097-1099.	1.4	0
1742	Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer. <i>Biomedicines</i> , 2022, 10, 2775.	1.4	5
1743	Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. <i>European Journal of Cancer</i> , 2023, 179, 136-146.	1.3	13
1744	Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?. <i>JCO Precision Oncology</i> , 2022, , .	1.5	0
1745	Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1765-1770.	0.9	1
1746	BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel. <i>Cancers</i> , 2022, 14, 5399.	1.7	2
1747	Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 51-56.	1.1	3
1748	A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. <i>Biochemical Pharmacology</i> , 2022, 206, 115329.	2.0	16
1749	Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor-Negative Advanced Breast Cancer in the United States, Europe, and Israel. <i>Advances in Therapy</i> , 2023, 40, 331-348.	1.3	4
1751	Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation. <i>Clinical Cancer Research</i> , 2023, 29, 432-445.	3.2	2

#	ARTICLE	IF	CITATIONS
1752	Germline findings in patients with advanced malignancies screened with paired blood-tumor testing for personalized treatment approaches. <i>European Journal of Cancer</i> , 2022, , .	1.3	0
1753	Development of a novel BRCAness score that predicts response to PARP inhibitors. <i>Biomarker Research</i> , 2022, 10, .	2.8	6
1754	Overview on population screening for carriers with germline BRCA mutation in China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1755	Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. <i>International Immunopharmacology</i> , 2022, 113, 109444.	1.7	6
1756	Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints. <i>Cancers</i> , 2022, 14, 5633.	1.7	6
1757	Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	4
1758	A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+CD24- enriched breast cancer stem-like cells. <i>Drug Resistance Updates</i> , 2023, 66, 100903.	6.5	7
1759	PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer. <i>European Medical Journal Oncology</i> , 0, , 68-76.	0.0	1
1760	Trilaciclib: A First-in-class Therapy to Reduce Chemotherapy-induced Myelosuppression. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 152.	0.1	1
1761	Current Standard Clinical Predictive Markers. , 2022, , 873-894.		0
1762	Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2023, 112, 102496.	3.4	18
1763	Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer. , 2023, 241, 108331.		2
1764	Testing for Inherited Susceptibility to Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 17-31.	0.9	0
1765	Breast Cancer Pathology in the Era of Genomics. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 33-50.	0.9	2
1766	Systemic Therapy for Hereditary Breast Cancers. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 203-224.	0.9	1
1767	Triple-Negative/Basal-Like Breast Carcinomas. , 2022, , 445-462.		0
1768	Management of Metastatic Triple-negative Breast Cancer: Focus on Targeted Therapies. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 98.	0.1	1
1769	Principalele abordări de profilare moleculară în oncologie: tehnologie, avantaje și limitări. <i>Oncolog-Hematolog Ro</i> , 2022, 4, 34.	0.0	0

#	ARTICLE	IF	CITATIONS
1770	Adolescent triple-negative breast cancer with germline pathogenic variants in both BRCA1 and TP53 genes: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1771	Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
1772	In-depth analysis of the expression and functions of signal transducers and activators of transcription in human ovarian cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1773	Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome. <i>Oxford Medical Case Reports</i> , 2022, 2022, .	0.2	1
1775	Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. <i>Cancers</i> , 2022, 14, 5795.	1.7	4
1777	Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1686-1698.	5.7	1
1778	PARG and BRCA1â€“BARD1 cooperative function regulates DNA repair pathway choice during gametogenesis. <i>Nucleic Acids Research</i> , 2022, 50, 12291-12308.	6.5	4
1779	Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. <i>Biomedicines</i> , 2022, 10, 3008.	1.4	0
1780	â€“Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical researchâ€“™. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1291-1310.	1.9	2
1781	Hereditary breast cancer: syndromes, tumour pathology and molecular testing. <i>Histopathology</i> , 2023, 82, 70-82.	1.6	18
1782	Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 489-501.	1.1	5
1783	Therapy of BRCA-associated metastatic breast cancer. Efficacy and safety of talazoparib in the real-world clinical practice. <i>Meditinskiy Sovet</i> , 2022, , 21-29.	0.1	0
1784	Genetic testing in privately insured women with surgically treated breast cancer. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
1785	Efficacy and safety of first-line carboplatin-paclitaxel and carboplatin-gemcitabine in patients with advanced triple-negative breast cancer: a monocentric, retrospective comparison. <i>Clinical Breast Cancer</i> , 2022, , .	1.1	4
1786	Update on tripleâ€“negative breast cancersâ€“%â€“%highlighting subtyping update and treatment implication. <i>Histopathology</i> , 2023, 82, 17-35.	1.6	13
1787	The BRCAness Landscape of Cancer. <i>Cells</i> , 2022, 11, 3877.	1.8	5
1788	Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study. <i>Breast Cancer</i> , 0, , .	1.3	0
1789	Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?. <i>Current Breast Cancer Reports</i> , 0, , .	0.5	0

#	ARTICLE	IF	CITATIONS
1790	The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	12
1791	Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1792	Neurologic complications of breast cancer. <i>Cancer</i> , 0, , .	2.0	0
1793	Genetic, Surgical and Oncological Approach to Breast Cancer, with <i>BRCA1, BRCA2, CDH1, PALB2, PTEN</i> and <i>TP53</i> Variants. <i>The Journal of Breast Health</i> , 2022, 19, 55-69.	0.4	1
1794	Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy and Precision Oncology</i> , 2023, 6, 31-49.	0.6	1
1795	Targeting DNA damage response pathways in cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 78-94.	12.8	158
1796	Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms. <i>Archives of Medical Research</i> , 2022, 53, 807-817.	1.5	1
1797	Understanding cancer genetic risk assessment motivations in a remote tailored risk communication and navigation intervention randomized controlled trial. <i>Health Psychology and Behavioral Medicine</i> , 2022, 10, 1190-1215.	0.8	0
1798	Evolving DNA repair synthetic lethality targets in cancer. <i>Bioscience Reports</i> , 2022, 42, .	1.1	3
1800	IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
1801	Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2â€“negative advanced breast cancer from the United States, Europe, and Israel. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
1802	Novel Implications of Prognostic Markers to Monitor the Disease: An Overview. , 2023, , 182-197.		0
1803	Role of Immunotherapy in Breast Cancer. <i>JCO Oncology Practice</i> , 2023, 19, 167-179.	1.4	19
1804	Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2023, 24, 162-174.	5.1	20
1805	Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. <i>Journal of Ovarian Research</i> , 2023, 16, .	1.3	8
1806	Breast cancer heterogeneity and its implication in personalized precision therapy. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	31
1807	How I treat HER2-low advanced breast cancer. <i>Breast</i> , 2023, 67, 116-123.	0.9	5
1809	STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. , 2023, 11, e005627.		17

#	ARTICLE	IF	CITATIONS
1810	PARP inhibitor olaparib induced differential protein expression in cervical cancer cells. <i>Journal of Proteomics</i> , 2023, , 104823.	1.2	0
1811	Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. <i>Cell Reports Medicine</i> , 2023, 4, 100915.	3.3	5
1812	Molecular Alterations and Putative Therapeutic Targeting of Planar Cell Polarity Proteins in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 411.	1.0	2
1813	New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2023, 6, 35-44.	0.9	0
1815	Retarding breast tumor growth with nanoparticle-facilitated intravenous delivery of BRCA1 and BRCA2 tumor suppressor genes. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
1816	Theranostics for Triple-Negative Breast Cancer. <i>Diagnostics</i> , 2023, 13, 272.	1.3	7
1817	Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study. <i>Journal of Medical Genetics</i> , 2023, 60, 760-768.	1.5	3
1818	An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1799.	1.8	6
1819	A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. <i>International Journal of Cancer</i> , 2023, 152, 2134-2144.	2.3	5
1821	Systemic treatments for breast cancer brain metastasis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1822	A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer. <i>Cancer Letters</i> , 2023, 555, 216049.	3.2	4
1823	Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review. <i>Cancer Treatment Reviews</i> , 2023, 114, 102511.	3.4	4
1824	Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family. <i>Gene</i> , 2023, 857, 147179.	1.0	0
1825	DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2539-2566.	1.3	0
1826	A Case of Recurrent Breast Cancer in which the Optimal Treatment was Selected Considering the Results of HER2 FISH and Genomic Diagnosis. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese)</i> Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50		
1827	Cancer risk-reducing surgery: Brazilian Society of Surgical Oncology Guideline Part 2 (Gastrointestinal and thyroid). <i>Journal of Surgical Oncology</i> , 2022, 126, 20-27.	0.8	1
1828	Understanding cancer predisposition in Singapore: What's next. <i>Singapore Medical Journal</i> , 2023, 64, 37.	0.3	2
1829	Triple-Negative Breast Cancer Therapy: Recent Advances, Challenges, and Future Perspective. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
1830	The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-8.	1.1	0
1832	SUMOylation of HNRNPA2B1 modulates RPA dynamics during unperturbed replication and genotoxic stress responses. <i>Molecular Cell</i> , 2023, 83, 539-555.e7.	4.5	8
1833	Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
1834	Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. <i>Annals of Oncology</i> , 2023, 34, 397-409.	0.6	10
1835	Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. <i>Molecular Cell</i> , 2023, 83, 660-680.	4.5	10
1836	Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA. <i>Cancer Research and Treatment</i> , 2023, 55, 1048-1052.	1.3	2
1837	The HER2-low revolution in breast oncology: steps forward and emerging challenges. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311528.	1.4	10
1838	Quality of Life is Essential: Implications for Diagnosis and Treatment for BRCA1/2 Germline Mutations. , 0, , .		0
1840	Pan-cancer onco-signatures reveal a novel mitochondrial subtype of luminal breast cancer with specific regulators. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	0
1841	Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
1842	Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211461.	1.4	5
1843	Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
1844	Mainstreaming of genomics in oncology: a nationwide survey of the genomics training needs of UK oncologists. <i>Clinical Medicine</i> , 2023, 23, 9-15.	0.8	4
1845	KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition. <i>Leukemia</i> , 2023, 37, 751-764.	3.3	4
1846	Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer. <i>Oncologist</i> , 0, , .	1.9	0
1848	Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy. <i>Cancers</i> , 2023, 15, 2194.	1.7	0
1849	A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors. <i>Oncologist</i> , 0, , .	1.9	0
1850	Deciphering breast cancer: from biology to the clinic. <i>Cell</i> , 2023, 186, 1708-1728.	13.5	72

#	ARTICLE	IF	CITATIONS
1851	Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. <i>British Journal of Cancer</i> , 2023, 128, 2072-2080.	2.9	0
1852	The potential of PARP as a therapeutic target across pediatric solid malignancies. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
1853	Instant Oncology: OlympiAD. <i>Clinical Oncology</i> , 2023, 35, 329-330.	0.6	0
1854	OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , 2023, 184, 39-47.	1.3	15
1855	A robust and lightweight deep attention multiple instance learning algorithm for predicting genetic alterations. <i>Computerized Medical Imaging and Graphics</i> , 2023, 105, 102189.	3.5	2
1856	Cancer riskâ€reducing surgery: Brazilian society of surgical oncology guideline part 1 (gynecology and) Tj ETQq1 1 0.784314rgBT /Over 0.8	0.8	1
1857	Mild photothermal therapy boosts nanomedicine antitumor efficacy by disrupting DNA damage repair pathways and modulating tumor mechanics. <i>Nano Today</i> , 2023, 49, 101767.	6.2	20
1858	PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 91, 203-217.	1.1	3
1859	Distinct breast cancer phenotypes in BRCA 1/2 carriers based on ER status. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 197-205.	1.1	0
1860	Metastatic Breast Cancer to the Spine: Incidence of Somatic Gene Alterations and Association of Targeted Therapies With Overall Survival. <i>Neurosurgery</i> , 2023, 92, 1183-1191.	0.6	0
1861	Suppression of GCH1 Sensitizes Ovarian Cancer and Breast Cancer to PARP Inhibitor. <i>Journal of Oncology</i> , 2023, 2023, 1-16.	0.6	0
1862	Copper complexes suppress stemness, reverse epithelialâ€toâ€mesenchymal transition progression, and induce apoptosis on triple negative breast cancer. <i>Applied Organometallic Chemistry</i> , 2023, 37, .	1.7	0
1863	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. <i>Cancers</i> , 2023, 15, 1093.	1.7	4
1864	Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow. <i>Journal of Clinical Oncology</i> , 2023, 41, 2767-2778.	0.8	5
1865	Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency. <i>Genomics, Proteomics and Bioinformatics</i> , 2023, , .	3.0	2
1866	Lessons from other fields of medicine, Part 1: Breast cancer. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2023, , 101-118.	1.0	2
1867	Prediction of carrying a BRCA1 or BRCA2 mutation. <i>Annals of Translational Medicine</i> , 2023, 11, 271-271.	0.7	1
1868	A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. <i>Journal of Advanced Research</i> , 2023, 54, 271-292.	4.4	15

#	ARTICLE	IF	CITATIONS
1869	Efficacy and safety of treatment regimens for patients with metastatic, locally advanced, or recurrent breast cancer carrying BRCA1/BRCA2 pathogenic variants: A network meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1870	Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC). <i>Journal of Clinical Medicine</i> , 2023, 12, 1524.	1.0	11
1871	Rucaparib or Physician's Choice in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2023, 388, 719-732.	13.9	104
1872	Anticancer Effects of Propolis Extracts Obtained Using the Cold Separation Method on Breast Cancer Cell Lines. <i>Plants</i> , 2023, 12, 884.	1.6	0
1873	How I treat endocrine-dependent metastatic breast cancer. <i>ESMO Open</i> , 2023, 8, 100882.	2.0	6
1874	A case of unresectable intrahepatic cholangiocarcinoma with a germline BRCA1 mutation. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	0
1875	Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. <i>Cancers</i> , 2023, 15, 1299.	1.7	5
1876	Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
1877	Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation. <i>Annals of Oncology</i> , 2023, 34, 315-318.	0.6	1
1878	Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. <i>Cancer</i> , 2023, 129, 1411-1418.	2.0	2
1879	Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
1881	Novel diagnostic biomarkers of T cell-mediated tumor killing characteristics for early-stage triple negative breast cancer: A SEER analysis and molecular portraits. <i>Medicine (United States)</i> , 2023, 102, e33059.	0.4	0
1882	Value of Conventional MRI, DCE-MRI, and DWI-MRI in the Discrimination of Metastatic from Non-Metastatic Lymph Nodes in Rectal Cancer: A Systematic Review and Meta-Analysis Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2023, 24, 401-410.	0.5	1
1883	Prevalence of Pathogenic Germline Mutations in 13 Hereditary Cancer-Related Genes in Breast Cancer Patients in Narathiwat Province, Thailand. <i>Asian Pacific Journal of Cancer Prevention</i> , 2023, 24, 525-530.	0.5	1
1884	Hereditary Breast Cancer and Pathogenic Germline Variants. , 2023, , 45-59.		0
1885	A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620). <i>Breast Cancer Research and Treatment</i> , 2023, 198, 487-498.	1.1	0
1887	Systematic review of the management of brain metastases from hormone receptor positive breast cancer. <i>Journal of Neuro-Oncology</i> , 2023, 162, 45-57.	1.4	6
1889	Personalized Systemic Therapies in Hereditary Cancer Syndromes. <i>Genes</i> , 2023, 14, 684.	1.0	4

#	ARTICLE	IF	CITATIONS
1890	Cost-effectiveness analysis of talazoparib and olaparib for breast cancer in adults. Medical Technologies Assessment and Choice (2023) 1(1):1-10.	0.1	0
1891	Clinical case study meets population cohort: identification of a BRCA1 pathogenic founder variant in Orcadians. <i>European Journal of Human Genetics</i> , 2023, 31, 588-595.	1.4	1
1892	Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 431-443.	1.2	11
1893	BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1894	Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets. <i>Cancers</i> , 2023, 15, 1855.	1.7	1
1895	Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 480-515.	157.7	23
1896	Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel. <i>Journal of Molecular Diagnostics</i> , 2023, 25, 295-310.	1.2	1
1897	Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	16
1898	Top advances of the year: Precision oncology. <i>Cancer</i> , 2023, 129, 1634-1642.	2.0	1
1899	What Is Known about Breast Cancer in Young Women?. <i>Cancers</i> , 2023, 15, 1917.	1.7	18
1900	Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline <i>BRCA</i> -Mutated Advanced HER2-Negative Breast Cancer. <i>Oncologist</i> , 0, , .	1.9	0
1901	Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead. <i>Current Treatment Options in Oncology</i> , 2023, 24, 442-465.	1.3	6
1902	Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer. <i>British Journal of Cancer</i> , 2023, 128, 1964-1975.	2.9	4
1903	Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. <i>Cell Research</i> , 2023, 33, 389-402.	5.7	13
1904	Olaparib efficacy in patients with germline <i>BRCA</i> -mutated, <i>HER2</i> -negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. <i>International Journal of Cancer</i> , 2023, 153, 803-814.	2.3	4
1905	Aptamer-Based Strategies to Boost Immunotherapy in TNBC. <i>Cancers</i> , 2023, 15, 2010.	1.7	5
1906	Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 2015.	1.7	3
1907	Targeting <i>BRCA</i> -mutant biliary tract cancer: Current evidence and future perspectives. <i>Journal of Digestive Diseases</i> , 2023, 24, 85-97.	0.7	3

#	ARTICLE	IF	CITATIONS
1908	Facing inevitable PARPi resistance: Mechanisms and therapeutic strategies for breast cancer treatment. , 2023, 1, .		2
1909	Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis. Breast Cancer Research and Treatment, 0, , .	1.1	0
1910	Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer. Nature Cancer, 2023, 4, 716-733.	5.7	5
1911	Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer. Current Oncology Reports, 2023, 25, 689-698.	1.8	2
1912	Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast Cancer, 2023, 30, 596-605.	1.3	3
1913	Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2023, 21, 351-358.e4.	2.3	3
1914	Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model. Journal of Controlled Release, 2023, 357, 287-298.	4.8	2
1915	A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA). ESMO Open, 2023, 8, 101207.	2.0	0
1916	Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC). Drug Development Research, 2023, 84, 629-653.	1.4	3
1917	Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer. Expert Opinion on Pharmacotherapy, 2023, 24, 789-801.	0.9	1
1918	Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. Cancers, 2023, 15, 2204.	1.7	10
1919	Recent advances in targeted therapy for pancreatic adenocarcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 571-595.	0.8	10
1920	Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer. Journal of Cellular Physiology, 0, , .	2.0	0
1921	The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers. International Journal of Molecular Sciences, 2023, 24, 7293.	1.8	2
1922	Complete Response Following Treatment with Olaparib in a Patient with BRCA-Mutant High-Grade Serous Ovarian Cancer and Central Nervous System Metastases. Indian Journal of Gynecologic Oncology, 2023, 21, .	0.1	0
1924	Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score. Breast, 2023, , .	0.9	3
1925	Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer. Breast Cancer Research, 2023, 25, .	2.2	4
1926	Targeted therapy. , 2023, , 205-411.		0

#	ARTICLE	IF	CITATIONS
1927	Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	1
1937	Clinical efficacy of PARP inhibitors in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 200, 15-22.	1.1	3
1961	The power of whole genomic sequencing in biomedical research and clinical applications. , 2024, , 1-18.		0
1966	Targeted Therapy and Personalized Medicine. <i>Cancer Treatment and Research</i> , 2023, , 177-205.	0.2	2
1987	Regulation of Biomolecular Condensates by Poly(ADP-ribose). <i>Chemical Reviews</i> , 2023, 123, 9065-9093.	23.0	3
2025	A HLUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-â†11q splice variant. <i>Oncogene</i> , 0, , .	2.6	1
2027	Management of Breast Cancer. , 2023, , 17-31.		0
2051	DNA as the main target in radiotherapyâ€”a historical overview from first isolation to anti-tumour immune response. <i>Strahlentherapie Und Onkologie</i> , 2023, 199, 1080-1090.	1.0	3
2062	An apparent quandary: adoption of polygenics and gene panels for personalised breast cancer risk stratification. , 2023, 1, .		1
2063	Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	4
2071	The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer. <i>Oncology and Therapy</i> , 0, , .	1.0	0
2074	Heterogeneity of the tumor immune microenvironment and clinical interventions. <i>Frontiers of Medicine</i> , 2023, 17, 617-648.	1.5	0
2077	CTCs in Early Breast Cancer. <i>Current Cancer Research</i> , 2023, , 463-490.	0.2	0
2079	Molecular tumour boards â€” current and future considerations for precision oncology. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 843-863.	12.5	6
2082	Molecular testing in breast cancer. , 2024, , 303-318.		0
2136	Emerging treatment approaches for triple-negative breast cancer. , 2024, 41, .		1
2140	Exploring the therapeutic potential of ADC combination for triple-negative breast cancer. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	2.4	0
2142	Combining PARP Inhibition and Immunotherapy in BRCA-Associated Cancers. <i>Cancer Treatment and Research</i> , 2023, , 207-221.	0.2	0

#	ARTICLE	IF	CITATIONS
2152	Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer. <i>Cancer Treatment and Research</i> , 2023, , 91-102.	0.2	0
2154	Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?. <i>Oncology and Therapy</i> , 2024, 12, 19-29.	1.0	1
2170	Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy. , 2024, 41, .		1
2172	Handling Germline Findings in Ovarian Cancer Cases. , 2023, , 129-141.		0
2187	Putting It All Together: Clinical Pearls of Recently Approved Therapies for Triple-Negative Breast Cancer. , 2023, , 65-76.		0
2188	Can We Find A Noninvasive Tool of Precision Medicine That Can Always Be Used For the Individualized Treatment of Women With Breast Cancer?. , 2023, , 96-107.		0
2202	Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer. <i>Cancer Treatment and Research</i> , 2023, , 29-62.	0.2	0
2203	Establishment of a Medical System with HBOC in Mind. , 2023, , 3-13.		0
2206	Antibody-Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer. <i>Cancer Treatment and Research</i> , 2023, , 1-27.	0.2	0